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ABSTRACT 
Gastric and esophageal cancer – gastroesophageal cancers, belong to the most fatal 
malignancies in the world. Understanding the cause of these diseases is key to interventions 
such as primary prevention and/or surveillance with the potential of lowering the disease 
burden. Several important exposures have been identified or suggested but the causes of 
gastroesophageal cancers are still largely unknown. Further, only one in three gastric cancer 
patients and one in six esophageal cancer patients are still alive five years after their diagnosis. 
The prognosis is considerably improved if the tumor can be surgically removed, but 70-80% 
of the patients are not eligible for surgery due to advanced spread of the disease at diagnosis. 
Both curable and non-curable gastroesophageal cancer patients may be treated with 
chemotherapy – but reports about the survival outcome from real-world patients based on the 
treatment they receive, are very scarce. In this thesis we explored important biological 
determinants for gastroesophageal cancers to encourage further research on their etiology. 
Furthermore, we did a follow-up study on the survival of gastroesophageal cancer patients who 
were treated with various chemotherapy regimens to determine their effectiveness in a real-
world setting. 
We used population-based registers in Sweden and a case-control study in a high-risk region 
to explore the association between biological risk markers and gastroesophageal cancers. In 
study I we employed the nationwide Stomach Biopsy Cohort (SBC) study in Sweden to 
estimate the risk for gastric cancer associated with family history of gastric mucosal lesions. In 
study II we used the Epidemiology Strengthened by histoPathology Reports in Sweden 
(ESPRESSO) study to explore the risk for gastroesophageal cancers associated with 
esophageal lesions. In study III, we performed a case-control study in a high-risk area in China 
to study the association between gastric atrophy and esophageal squamous cell carcinoma, and 
examine its interaction with poor oral health, which might further increase the risk of 
esophageal squamous cell carcinoma. In study IV, we explored the influence of various 
chemotherapy regimens on the survival of gastroesophageal cancer patients based on a regional 
study on cancer chemotherapy at the Regional Cancer Center in Stockholm-Gotland. 
In study I, we found that the excess risk was 50-60% higher for gastric non-cardia cancer 
among individuals who had a first-degree relative with gastric mucosal lesions (atrophic 
gastritis/intestinal metaplasia/dysplasia) compared to the general Swedish population. In study 
II, we demonstrated that non-dysplastic gastric and glandular metaplasia patients had a similar 
excess risk (Standardized Incidence Ratio, SIR 11.9; 95% 95% Confidence Interval, CI, 9.9-
14.1) for esophageal adenocarcinoma as intestinal metaplasia patients (SIR (10.8; 95% CI 7.8-
14.6). In study III, we confirmed an association between gastric atrophy and esophageal 
squamous cell carcinoma (Odds Ratio 1.61; 95% CI 1.33-1.96), which was further increased 
in the presence of poor oral health (Relative Excess Risk due to Interaction 1.28; 95% CI 0.39-
2.18). In study IV, we discovered that among patients who were intended to have curative 
treatment, esophageal cancer patients who received cisplatin-fluorouracil had better survival 
than those with carboplatin-fluorouracil (Hazard Ratio, HR, for carboplatin-fluorouracil vs 
cisplatin-fluorouracil 2.18; 95% CI 1.09-4.37), but gastroesophageal junction cancer patients 
treated with cisplatin-fluorouracil had worse survival than patients with fluorouracil-oxaliplatin 
(HR for fluorouracil-oxaliplatin vs cisplatin-fluorouracil 0.28; 95% CI 0.08-0.96). 
We conclude that family history of gastric mucosal lesions can be employed for further risk 
stratification for non-cardia gastric cancer but needs to be evaluated regarding cost-
effectiveness. Further, non-dysplastic columnar metaplasia patients may benefit from 
strengthened surveillance, but further validation studies are required. Moreover, gastric atrophy 
and its interaction with poor oral health are associated with esophageal squamous cell 
carcinoma in a high-risk region in China, thus future studies of the microbial alterations 
associated with gastric atrophy and poor oral health in the development of esophageal 
squamous cell carcinoma are warranted. Last, the choice of cisplatin-fluorouracil was 
associated with better survival outcome in esophageal but worse outcome in gastroesophageal 
junction cancer patients in Sweden. This finding needs to be further explored on a national 
level in Sweden. 
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1 INTRODUCTION 
According to the most recent report from the International Agency for Research on Cancer 
(IARC), there were around 0.7 million deaths from stomach cancer and 0.4 million deaths from 
esophageal cancer in 2012. In terms of number of cancer deaths, these cancers rank third and 
sixth worldwide (1). In the same year, there were an estimated 0.95 million and 0.48 million 
incident cases. The high mortality to incidence ratio implies a poor prognosis, not only because 
of the aggressive growth that characterizes these malignancies, but also because these cancers 
are more common in developing countries, where most cases are first diagnosed at an advanced 
stage. Japan – a high-risk country for gastric cancer – is an exception to the high mortality: 
incidence ratio from gastric cancer. Early diagnosis of gastric cancer has proven effective in 
Japan, where the 5-year survival rate is above 90% mainly due to a screening program and 
early intervention. This is outstanding compared to other countries, including Europe where 5-
year survival rates are much lower, 10-25% (2). The combination of high incidence and good 
prognosis could also be due to overdiagnosis at screening; however, there is no current 
standardized method of estimating this (3). Screening programs would, however, not be 
feasible for gastric and esophageal cancers in low-risk areas such as Sweden. Better 
understanding of the etiology of both cancers could help risk-stratifying patients and allow for 
primary prevention, targeted screening and surveillance of high-risk individuals. Such 
strategies would be potentially successful for helping more patients survive gastric and 
esophageal cancers in low-risk countries.
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2 BACKGROUND 
2.1 THE BURDEN OF ESOPHAGEAL AND GASTRIC CANCER 
2.1.1 Classification 
Esophageal cancer displays two major histological types: esophageal squamous cell carcinoma 
(ESCC) and esophageal adenocarcinoma (EAC). ESCC is the predominant type, accounting 
for 88% of all new cases in 2012 worldwide (4).  
Unlike esophageal cancer, the main histologic type of gastric cancer is adenocarcinoma, 
accounting for more than 90% of the cases (5). Other rarer histopathologic types are lymphoma, 
leiomyosarcoma (5) and neuroendocrine tumors (6). 
By anatomic site, gastric cancer can also be divided into cardia and non-cardia gastric cancer 
(5). Although there is no present consensus on the anatomical definition, the proximal cardia 
cancer and the more distal non-cardia gastric cancer have different risk factors (5). The 
incidence of gastric cancer has declined from the most common cancer in the 1975 to the fifth 
most common cancer in 2018 (7). Declining incidence of non-cardia gastric cancer has been 
suggested to be mainly due to a decrease of Helicobacter pylori (H. pylori) infection (5). 
According to some previous studies, the incidence of gastric cardia cancer has continued to 
increase, which might partly be explained by improved classification (8). 
Laurén’s histopathological subdivision of gastric carcinomas into intestinal-type and diffuse-
type, based on the histological appearance, is commonly used and has been linked to clinical 
characteristics, pathogenesis pathways and prognosis (9). The pathogenesis of intestinal-type 
gastric cancer is described as Correa’s cascade and is well established (10). It is probably 
promoted by H. pylori infection and progresses from chronic superficial gastritis to atrophic 
gastritis, then intestinal metaplasia, dysplasia and ultimately gastric cancer. However, diffuse-
type gastric cancer has not been associated with a similar pathological pathway as intestinal-
type gastric cancer (11). 
The most recent WHO definition of gastric adenocarcinomas (published in the fifth edition of 
the WHO Classification of Digestive System Tumors) uses yet another histological 
classification based on five main groups: papillary, tubular, mucinous, poorly cohesive and 
mixed. 
Although the previous histopathological and anatomical classifications have been useful for 
prognosis assessment, new molecular definitions are gaining popularity to predict treatment 
response. Based on gene expression profiling, the Cancer Genome Atlas Research Group 
(TCGA) (12) and the Asian Cancer Research Group (ACRG) (13) have developed new 
molecular classification systems for gastric adenocarcinoma. By performing several molecular 
analyses (whole exome sequencing, somatic copy number analysis, DNA methylation 
profiling, messenger and microRNA sequencing and protein analysis) of chemotherapy-naïve 
gastric cancer samples, the TCGA system has identified four subtypes: EBV-positive (EBV), 
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microsatellite unstable (MSI), chromosomally unstable (CIN) and genomically stable (GS) 
(12). The subtypes identified in the TCGA system are gaining popularity in research and have 
been validated in subsequent patient cohorts (14, 15), but are not yet utilized as much in the 
clinical setting (16, 17). 
The only exception to this is the assessment of an overexpression of the HER2 gene which is 
currently the only routine diagnostic test used for both esophageal and gastric adenocarcinoma 
patients (16). This is mainly due to the significant survival benefit that was demonstrated in the 
ToGA trial in 2010 (18) for advanced gastroesophageal adenocarcinoma patients who received 
add-on treatment with trastuzumab (a HER2 antibody) in the cisplatin-fluoropyrimidine-
trastuzumab arm, and in particular within a subgroup of HER2-positive patients.  
Molecular markers as a basis for gastroesophageal cancer classification therefore may have a 
brighter future potential than classical anatomical definitions to personalize treatments and 
improve the prognosis within subgroups of gastroesophageal cancer patients (19). 
2.1.2 Geographical distribution 
The two subtypes of esophageal cancer display remarkably different incidence patterns and 
geographical distribution. ESCC is predominant in less developed countries, especially in the 
South-Eastern, Central Asian regions and China where over 79% of all ESCC cases occur. 
EAC however has shown rapidly increasing incidence in Northern and Western Europe, 
Northern America and Oceania where 46% of the global EAC cases occur (20). A dramatic 
increase in the incidence of EAC was noted in eight registries from Australia, North America, 
Europe and Asia with an estimated start sometime between 1960 and 1990, where calendar 
period rather than birth cohort was the more important determinant of incidence trend (21). 
Some countries such as the UK, the Netherlands, Iceland, Norway and Sweden currently have 
higher incidence rates of EAC than ESCC. 
Gastric cancer is most common in Eastern Asia, Eastern Europe and South America, where the 
estimated age-standardized incidence rates in 2018 were highest with 12.7-32.1 in men and 
6.9-13.2 in women per 100 000 person-years (7). About half of the total gastric cancer cases 
were located in Eastern Asia, and the age-standardized incidence rate was twice as high for 
males compared to females (especially in the Republic of Korea, Mongolia, Japan and China) 
(7, 11). Ethnicity has been associated with the incidence of gastric cancer as well. In the US, a 
low-risk country for gastric cancer with an overall age-adjusted incidence rate between 2012 
and 2016 of 7.4/100 000, the incidence in Caucasians was 6.6/100 000 compared to almost the 
doubled rate of 10.3/100 000 in individuals with Afro-American origin (22). Individuals who 
have migrated from areas with high incidence of stomach cancer to low-risk areas display 
similar risk of gastric cancer as the country of origin, while subsequent generations have shown 
decreased incidence rates, demonstrating complex host-environmental interactions in the 
development of gastric cancer (11). 
The most recent edition of the Textbook on Cancer Epidemiology from 2018 (23) states that 
the rather dramatic geographical variations in esophageal cancer incidence together with a low 
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explanatory proportion of genetic mutations may imply that external factors, in part enhanced 
by genetic susceptibility, play an important role in the pathogenesis of esophageal cancer. This 
description is applicable to gastric cancer as well. A recent analysis of the global burden of the 
five major gastrointestinal cancers from the GLOBOCAN 2018 data suggests that life-style 
choices are the driving factors behind the past and future burden of GI cancers (24). 
2.1.3 Age distribution 
The incidence of gastroesophageal cancers increases with age and mainly affects patients 60-
80 years of age (25, 26). Only a minority of patients are diagnosed with gastroesophageal 
cancers under the age of 40 (22, 27). The incidence of esophageal adenocarcinoma (28) and 
gastric non-cardia adenocarcinoma has been increasing in younger men (29, 30) which might 
indicate other etiological factors than among older patients. 
2.1.4 Sex differences 
There is a marked male predominance in incidence of both ESCC (2-4 fold more common in 
males) and EAC (8-fold more common in males), but the molecular mechanisms for this 
difference are not yet clear (31). 
Overall, there is a male predominance in incidence of gastric cancer, but limited data indicate 
this does not hold true for all age groups and subtypes of gastric cancer (29, 32, 33). The 
mechanism behind these differences is unknown, but previous studies have suggested female 
hormones such as estrogen are protective against the risk of gastric cancer (34). Unlike other 
sex-hormone dependent cancers such as breast cancer and prostate cancer, the role of sex 
hormone receptors has not yet been established in gastric cancer (32). 
Like for gastric cancer, estrogen has also been suggested as the factor protecting women and 
explaining the male predominance of esophageal cancer, particularly esophageal 
adenocarcinoma. There is, however, limited data showing a steady decline with age in the sex 
ratio for esophageal adenocarcinoma, which may indicate factors other than estrogen behind 
the male predominance of esophageal adenocarcinoma (34). 
2.1.5 Environmental risk factors 
2.1.5.1 Dietary factors 
Dietary factors have been hypothesized to play a major role in high-risk areas for ESCC. 
However, the highly-anticipated chemoprevention trial investigating supplementation of 
vitamins and minerals for risk reduction of ESCC has shown null effects (35).  
A positive association between salt intake and gastric cancer was first reported in an 
observational study from Japan in 1959. Experimental studies support the link between high 
salt intake and gastric cancer development in interaction with H. pylori infection but not alone 
(36). 
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High intake of fruit and vegetables has been reported to reduce the risk of gastric cancer. A 
meta-analysis reported that the pooled relative risk (RR) for gastric cancer associated with 
consumption of fruits was 0.82 (95% CI 0.73-0.93), and even lower when the follow-up period 
was longer than 10 years (RR=0.66, 95% CI 0.52–0.83); for vegetables it was 0.88 (95% CI 
0.69–1.13) and 0.71 (95% CI 0.53-0.94), respectively (37). 
Whether high intake of red and processed meat is a risk factor for gastric cancer still remains 
inconclusive. A recent systematic review and meta-analysis reported a positive association in 
case-control studies for red meat and processed meat, where the summary relative risk of 
highest versus lowest consumption was 1.67 (95% CI 1.36-2.05), and 1.76 (95% CI 1.51-2.05), 
respectively. Cohort studies, however, reported no associations with gastric cancer (for red 
meat: RR=1.14 (95% CI 0.97-1.34); for processed meat: RR=1.23 (95% CI 0.98-1.55). Subtype 
analysis yielded similarly null results for both cardia cancer and non-cardia gastric cancer (38).  
2.1.5.2 Helicobacter pylori 
In normal stomachs, or those affected only by superficial gastritis, the high acidic environment 
prohibits colonization of bacteria other than H. pylori. However, with the development of 
atrophic gastritis, the hypo- or achlorhydric stomach provides an environment that facilitates 
bacterial overgrowth. Some species in the microbiota may reduce nitrate to nitrite by nitrate 
reductase or produce enzymes capable of catalyzing N-nitrosation (39). We hypothesized that 
enhanced endogenous production of nitrosamines, which are transported to the esophagus by 
some still unknown mechanisms, might be the underlying mechanism for the observed 
association between gastric atrophy and ESCC. N-nitroso compounds have been proposed to 
play a role in the pathogenesis of upper gastrointestinal cancer, and show organ-specific effects 
in animal models. 
To support this hypothesis, in a previous study we found that severe corpus atrophic gastritis 
was a strong risk factor for ESCC (40). This novel finding was later verified in studies with 
endoscopy data conducted in high-risk populations in Japan (41, 42), and in Brazil (43). One 
of these studies also reported an increasing risk for ESCC with increasing severity of atrophy; 
the multivariate-adjusted odds ratio with 95% confidence interval for histologic fundic atrophy 
was 4.2 (1.5-11.7), and 10.7 (2.3-50.4) for fundic intestinal metaplasia (42). Another study 
from Japan also reported an increased risk of ESCC in patients with profound hypochlorhydria 
(measured by endoscopic gastrin test) with an odds ratio of 6.0 (1.9-18.4) (44). In line with 
this, another small Japanese study (n=28) reported higher prevalence of hypochlorhydria 
(measured by 24-h pH-Impedance Monitoring) in the ESCC group, as well as a significantly 
higher number of total reflux and non-acid reflux episodes in the ESCC group versus non-
ESCC group (45). A cohort study in the Netherlands with data from a histopathological register 
also reported an increased risk of ESCC in patients with gastric atrophy; however, they could 
not confirm that the excess risks increased with increasing severity of gastric atrophy, and 
concluded that confounding factors such as smoking could explain the observed association 
(46). Further, two other studies, one from Germany (47) – a low risk area for ESCC (measuring 
fundic gastric atrophy by serology and histology) – and the other from Linxian in China (48) – 
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a high-risk area for ESCC (measuring gastric atrophy by serology) – did not find a statistically 
significant association. Overall, the results regarding the association between ESCC and gastric 
atrophy are inconsistent. Variations in findings might be explained by differences in study 
design, reliability of the method for gastric atrophy measurement, whether atrophy was 
assessed before, during or after cancer diagnosis, cancer stage, appropriate control of potential 
sources of biases and confounding, etc. Further studies are therefore needed to explore the 
potential role of gastric atrophy in ESCC. 
Moreover, poor oral health with an altered bacterial flora in the oral cavity might further 
contribute to the ESCC risk by adding more carcinogens to the esophagus. Poor oral health has 
been reported as an independent risk factor for ESCC in high-risk areas (49). This was recently 
confirmed by a study from our group in a high-risk population in China (50). In a study 
performed by our group in Iran, another high-risk area for ESCC, a possible interaction between 
gastric atrophy and poor oral health was reported, though the study was underpowered (51). 
H. pylori infection seems to be inversely associated with EAC (52).  
H. pylori was classified as a class I carcinogen for humans in 1994 (53). It affects about 50% 
of the global population (11), causing gastritis in most infected individuals, though many 
infected people are asymptomatic (53). Depending on complex interactions between 
environmental factors, bacterial virulence factors and host factors some H. pylori infections 
eventually lead to gastric cancer development (11).  
H. pylori eradication has successfully reduced the risk of progression in individuals with lesions 
such as gastritis and gastric atrophy; meanwhile, results regarding the influence on progression 
of intestinal metaplasia have been inconsistent (11). Pooled data from placebo-controlled H. 
pylori eradication trials in Asia have shown moderate-quality evidence that H. pylori 
eradication in healthy asymptomatic patients has a protective effect against gastric cancer with 
a relative risk of 0.66 (95% CI 0.46-0.95) compared to no treatment (54). 
2.1.5.3 Gastroesophageal reflux and obesity 
For EAC and gastric cardia adenocarcinoma, gastroesophageal reflux and obesity have been 
established as risk factors (26, 55). 
2.1.5.4 Smoking and alcohol 
Risk factors for ESCC suggested in previous studies include tobacco smoking, alcohol 
consumption and history of head and neck cancer. The risk estimates for ESCC associated with 
smoking and alcohol consumption vary many-fold between different populations and is 
believed to contribute more to the excess risk in the economically developed countries than the 
economically developing. Interaction between heavy smoking and heavy alcohol drinking has 
been reported in many studies, but not all cohort studies have been able to verify this effect 
modification which might be due to selection bias (49). 
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There is sufficient evidence that smoking causes stomach cancer according to the IARC 
monographs in 2004 on tobacco smoking (56), and further confirmed in 2012 (57). The 
conclusion is based on numerous cohort and case-control studies summarized in several 
systematic reviews and meta-analyses (58-61). However, conflicting results were reported 
when subdividing gastric cancer by histological subtype or anatomical site, which might be due 
to misclassification of gastric cancer subtypes, scarcity of studies with focus on subtypes of 
gastric cancer and publication bias. The study selection in the different meta-analyses is quite 
different despite overlapping time-periods, which might also explain some of the heterogeneity. 
2.1.5.5 Socioeconomic status 
Low socioeconomic status (SES) with surrogate markers such as low education, low income, 
higher number of siblings, overcrowding and lower occupational activity, is an established risk 
factor for gastric cancer, especially non-cardia cancer. Low SES however correlates with 
possible biological exposures for gastric cancer such as higher possibility of H. pylori infection, 
lower consumption of fruits and vegetables, smoking and physical inactivity. These factors are 
particularly likely to explain the observed association between low SES and gastric cancer (62). 
Indeed, in a large European multicenter study, adjustment for H. pylori infection rendered a 
null association between SES and gastric cancer (63). 
2.1.5.6 Medication use 
Use of aspirin and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) have been associated 
with a risk reduction of esophageal and gastric cancer (64, 65) while proton pump-inhibitors 
have been hypothesized to increase the risk (66). When dealing with medication use, 
confounding by indication cannot be ruled out (67, 68). 
2.1.6 Familial aggregation and genetic risk factors 
Familial aggregation has been reported to occur in roughly 10% of gastric cancer cases (69), 
wherein first-degree relatives of patients with gastric cancer have a 2-3 fold increased risk of 
developing gastric cancer compared to the general population (70, 71). Previous studies have 
also reported an increased prevalence of precancerous lesions such as atrophic gastritis (72), 
intestinal metaplasia (73) and dysplasia (74) in first-degree relatives of gastric cancer patients. 
However, to date, no previous study has reported the risk of gastric cancer in first-degree 
relatives of patients with precancerous lesions such as atrophic gastritis, intestinal metaplasia 
and dysplasia. 
The mechanisms for familial aggregation of gastric cancer are not clear. Genetic susceptibility, 
shared environmental exposures and common lifestyle habits such as cigarette smoking, diet, 
bacterial virulence and gene-environment interactions have been suggested to play a role (75). 
In line with this reasoning, there is growing evidence in support of non-cardia gastric cancer as 
a complex multi-cause disease where the development requires a long-term interplay between 
the host and the environment (including H. pylori related factors such as virulence and host 
genetics, as well as life-style factors) (76) already starting in childhood (77). This way of 
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understanding the disease could explain the higher elevated risk seen among siblings of gastric 
cancer patients (78). The complex interplay between H. pylori and host responses is somewhat 
illustrated by the identified host-related genetic polymorphisms of cytokines involved in the 
inflammatory response to H. pylori, which have been associated with both gastric pre-
malignant lesions and gastric cancer (76). In addition, H. pylori genetic polymorphisms, 
primarily related to the virulence, have also been linked to gastric non-cardia cancer (79).  
A minority (about 1-3%) of incident gastric cancer cases are considered to be hereditary (69). 
These are divided into three major syndromes: hereditary diffuse gastric cancer (HDGC), 
gastric adenocarcinoma and proximal polyposis of the stomach, and familial intestinal gastric 
cancer (69). HDGC is associated with mutations in the gene CDH1 (encoding E-cadherin) 
which is a tumor suppressor gene, and the gene CTNNA1 (encoding alpha-E-catenin) (69).  
Besides these three major syndromes, gastric cancer is also prevalent in other cancer-associated 
hereditary syndromes such as Lynch syndrome, Peutz-Jeghers syndrome and familial 
adenomatous polyposis (FAP) (69).  
2.1.7 Esophageal precursor lesions 
EAC incidence is increasing and it is important to better understand the pathogenic mechanisms 
to find high-risk groups for targeted primary prevention. Barrett’s esophagus (BE) is a 
condition where metaplastic columnar epithelium replaces the normal stratified squamous 
epithelium of the esophagus with gastroesophageal reflux as the main risk factor (80). Previous 
studies have estimated the risk of developing EAC in BE patients to be between 10 to 55 times 
higher than the general population (81). BE is the only known precursor lesion to EAC to date, 
but 95% of EAC patients did not have a previous diagnosis of BE in a previous study (82). BE 
incidence has been reported to increase in several studies from developed countries, but it is 
not clear if this is the main reason behind the increasing EAC incidence. BE patients are under 
surveillance by endoscopy in several countries, but the cost-effectiveness of such surveillance 
is undermined since most BE patients die from other causes than EAC (83). A randomized 
controlled trial is ongoing among BE patients in the UK to find out how endoscopic 
surveillance versus no endoscopic surveillance (endoscopy “at need”) affects early mortality 
and malignant transformation to esophageal adenocarcinoma (84). The final study report after 
study completion in 2022 hopefully will shed light on this issue. 
Squamous dysplasia is the established premalignant lesion for ESCC (85-87). However, 
previous studies were conducted mainly in high-risk areas, and studies from low-risk areas, 
such as Sweden, are still scarce. 
2.1.8 Treatment of gastroesophageal cancers 
2.1.8.1 Treatment guidelines 
Historically, the choice of treatment mainly depended on the localization and stage of the 
tumor. Histology has started to play a more significant role only recently. The current treatment 
guidelines for gastroesophageal cancers in Sweden have been established in collaboration 
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between Regional Cancer Centers. According to the current guidelines, early esophageal and 
gastric cancer (T1aN0M0) and intraepithelial neoplasia are treated with endoscopic mucosal 
resection with results comparable with traditional surgical resection.   
Cervical or proximal tumors of the esophagus need certain considerations regarding surgery 
when it comes to saving the larynx, and curative radiochemotherapy without surgery is also an 
option. Middle and lower esophageal cancers and gastric cancer are treated in a similar fashion 
with neo-adjuvant chemotherapy, with or without radiotherapy, and surgical resection.  
Current standard chemotherapy for ESCC is paclitaxel and carboplatin according to the 
CROSS study. For esophageal and gastric adenocarcinoma, the FLOT-regimen (5-Fu + 
kalciumfolinat + oxaliplatin + docetaxel) from the FLOT4 trial in 2016 is currently the standard 
chemotherapy.  
Palliative treatment for advanced gastroesophageal cancer with distant metastases follows the 
same guidelines with possible surgical treatment, chemo- or radiotherapy in order to alleviate 
symptoms (25). 
Although the efficacy is known for the chemotherapy regimens from previous clinical trials, 
head-to-head comparisons of commonly used perioperative chemotherapy from the post-
marketing clinical setting are scarce. To our knowledge, a real-world comparison of neo-
adjuvant chemotherapy in gastroesophageal cancer patients, separating patients who received 
surgery with curative intention from those with palliative treatment intention, has not been 
reported previously in Sweden. 
2.1.8.2 Studying oncology treatments in a real-world setting 
A “real-world setting” is, in our opinion, defined as an observational setting where data from 
existing health care registers and administrative registers are retrieved to study the effects of 
various exposures on an unselected population, in contrast to a clinical trial. However, several 
other definitions exist for real-world data (88).  
Evaluations of the kind we performed in study IV are restricted in Sweden due to the limited 
access to inpatient chemotherapy data. Our study was only made possible by the temporary 
register “SALT” that contains inpatient chemotherapy data from 2008 to 2014. To gain access 
to comprehensive inpatient chemotherapy data before or after 2014 one needs to extract the 
drug information in the medical records systems. Before 2008 there were several electronic 
medical systems in the same region, but in 2014 most health-care providers in Stockholm-
Gotland changed to TakeCare, following a regional decision to work in the same electronic 
medical records system. Studying chemotherapy regimens based on TakeCare would most 
likely require manual collection of chemotherapy data for each case. It is not unlikely that our 
situation with limited access to high-quality inpatient chemotherapy data is the same in many 
other countries, which probably can explain why this kind of evaluations are very rare. 
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Evaluations of this kind might however be more feasible in Sweden in the future. The quality 
register for gastroesophageal cancer (NREV) collects data about chemotherapy and 
radiotherapy given to this patient group. The completeness of these variables is quite poor for 
the period 2008-2014, but will hopefully improve from this time forth. 
Performing a clinical trial is the gold-standard method to establish the benefit-risk ratio of new 
chemotherapy regimens in gastroesophageal cancer patients. Studying how these results 
translate to “real-world” settings is however pivotal for decision makers, care-givers and 
patients. The real world setting differs in many aspects from a clinical trial. Clinical trials 
typically do not include all ethnicities in the population, the frail and elderly, patients with all 
tumor stages, the palliative patients, those with co-morbidities, polypharmacy and so on. These 
patients, however, are to be treated in the real world and what the benefit-risk ratio is among 
them is therefore often unknown prior to treatment. In our study IV we included all patients 
with incident cancer except those who were not planned to have any tumor-specific treatment 
at diagnosis, since we wanted to study the effect of treatment in a real-world setting. 
2.1.8.3 Precision medicine 
The exact definition of precision medicine varies but usually entails individually tailored 
prevention and/or treatment taking into account individual variations in tumor molecular 
characteristics, and host genetic or other factors. The research community has very high hopes 
for precision medicine in gastroesophageal cancers, since the classical definitions and 
treatments have not been overwhelmingly successful yet. Although new molecular/genetic 
definitions have been introduced and could be used for new drug targets, very little of the 
research findings have made it into clinical practice due to various hinders in data management, 
tumor- and patient-related factors (89-92). 
3 AIMS 
Although some common epidemiological risk factors have been established, the causes of 
gastroesophageal cancers and the treatment factors determining the prognosis are not fully 
understood. Therefore, the overall aim of this thesis is to elucidate biological factors 
associated with an elevated risk for gastroesophageal cancers, and evaluate treatments 
influencing the survival of gastroesophageal cancer patients in a real-world setting. 
More specifically, the aims are as follows: 
 Estimate the risk for gastric cancer among first-degree relatives of patients with gastric 
premalignant lesions. 
 Assess the gastroesophageal cancer risk associated with esophageal lesions. 
 Validate the elevated risk for ESCC associated with gastric atrophy and explore its 
interaction with poor oral health. 
 Compare the effectiveness on the survival of gastroesophageal cancer patients 
depending on the chemotherapy regimen they received. 
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These over-arching aims were addressed in the papers included in this thesis by the following 
research questions: 
Paper I 
 What is the risk for gastric cancer among parents, siblings and children to patients with 
gastric mucosal lesions based on a histopathology register study in Sweden? 
Paper II 
 What is the risk for esophageal adenocarcinoma associated with intestinal metaplasia 
in a population-based histopathology register study in Sweden? 
 What is the risk for gastroesophageal cancers associated with other histophatological 
esophageal lesions in Sweden? 
Paper III 
 What is the risk for esophageal squamous cell carcinoma associated with gastric 
atrophy, measured by serum pepsinogen levels, in a case-control study in a high-risk 
region in eastern China? And does the interaction with poor oral health further increase 
the risk? 
Paper IV 
 How did the various chemotherapy regimens used in Stockholm-Gotland during 2008 
to 2013 influence the survival of gastroesophageal cancer patients? 
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4 MATERIALS AND METHODS 
4.1 RESEARCH APPROACH 
The research approach in this thesis has been to address new questions about the pathways to 
gastroesophageal cancer and their prognosis by using tools from classical cancer epidemiology 
and biostatistics. Where it was suitable for the research question, we used existing health care 
registers in Sweden, sometimes complemented with our own data collection. The use of 
existing resources has the advantage of being both cost-effective and ethically sound. 
Furthermore, the national health care registers have nearly complete coverage and have been 
validated for research purposes. However, there are important limitations with administrative 
health care registers when used for research purposes. One limitation is the lack of reliable 
information on possible confounding factors, including smoking, alcohol consumption, BMI, 
diet, or biological confirmation such as histology. Furthermore, biochemical, molecular or 
genetic samples are seldom available. Another limitation is non-random missingness, such as 
TNM-stage. Selection bias is a potential issue, wherein the data from the register may not be 
representative of the source population of interest (for instance if studying alcoholism from the 
Patient Register or use of NSAIDs from the Prescribed Drug Register). Moreover, systematic 
error cannot be addressed easily in register-based studies since the researcher has no control 
and perhaps even limited insight with regards to the data collection process. Given these 
shortcomings, register-based research can be very useful if handled with caution and with close 
collaboration with those generating the data to be able to account for the limitations and sources 
of error that may be present. 
The research questions in the first two studies were addressed using data from the Swedish 
histopathology registers linked through the Personal Identity Number (PIN) to several national 
health care registers and other administrative registers to obtain individual level data on 
outcomes and potential confounding factors. In the third study, we designed and performed a 
large scale case-control study in a high-risk area in China to validate the results from a previous 
study in Sweden and Iran. In the last study, we used a similar register-based approach as the 
first two studies, with the modification that this study was based on information about 
individual chemotherapy treatments delivered to hospital patients.  
Below is a description of the key data sources and statistical methods employed, as well as the 
rationale for choosing these data and methods.  
4.2 DATA SOURCES 
4.2.1 Registers 
4.2.1.1 Histopathology registers 
The pathology departments in Sweden receive pathology and cytology samples on a daily basis 
for health care purposes such as diagnosis and treatment. Residual paraffin-embedded 
specimens from this process are stored for future use in connection with data of care or 
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treatment for that patient. The pathology departments thereby maintain the largest tissue 
biobanks in Sweden. Each department has a separate data register using one of two pathology 
records (SymPathy or Safir) to keep track of the specimens in their biobank.  The information 
stored is similar between the departments. The registers contain the personal identity number 
(PIN), date of the sample arrival, referral type and number, and the diagnosis based on the 
second edition of the SNOMED (Systemized Nomenclature of Medicine) system from the 
College of American Pathologists 1979. The first computerized records started in the 1970s, 
but large-scale computerization of records was seen close to the 1980s. By the late 1990s, all 
pathology departments had computerized their records. Besides their clinical use, the 
histopathology registers give unique possibilities for researchers to study certain clinical 
research questions that may not be feasible otherwise. The availability of these register data 
have allowed for the examination of, for example, the morphological, molecular and genetic 
alterations before and after disease diagnosis, as well as how different subgroups differ 
clinically, such as men versus women or younger versus older individuals. Biomedical 
researchers who want to use these biobank registers and/or specimens can apply to each 
department separately and ask for permission to do so. Applications are assessed by an 
independent group with medical professionals at each pathology department regarding ethical 
aspects, feasibility, patient benefit, how to cover costs and allocate resources. It is up to each 
pathology department to decide if and how they want to participate in research projects. The 
decision is always weighed against their top priority to maintain timely services to referring 
health care providers.  
Although most departments are very helpful and willing to contribute to research, the process 
of doing multi-center research with all the pathology departments in Sweden involves long 
lead-times and is resource-consuming for both the pathology department and the researcher. 
This has restricted the use of the histopathology registers in scientific research and they are 
therefore not validated as thoroughly as compared to many other national health registers in 
Sweden. 
A strength of the histopathology register is the use of the same coding system; the SNOMED 
II system across the whole country since the 1970s, enabling nationwide studies over many 
decades. However, the SNOMED II system is not maintained centrally by the SNOMED 
organization since it was replaced by newer SNOMED systems such as SNOMED III and later 
the SNOMED CT system. Consequently, a limitation with the SNOMED II system is that there 
is no centralized update of the system. Further, the coding system is no longer entirely uniform 
between counties and departments. Although efforts are being made by the Swedish 
Association for Pathology to spread standard diagnosis criteria and codes across the country, 
local variations between the different pathology departments exist.  
4.2.1.2 Population-based health registers and population registers 
Besides the National Board of Health and Welfare (Swedish: Socialstyrelsen) and Statistics 
Sweden (Swedish: Statistiska Centralbyrån) which are the two main authorities that own and 
maintain many of the population-based health and demographic registers in Sweden, there is a 
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large number of National Quality Registers that are supported by the state and the Swedish 
Association of Local Authorities and Regions, but maintained by various care-givers. 
Currently, just over one hundred National Quality Registers are active. A brief overview of the 
population-based health registers used in this thesis is given below. 
4.2.1.2.1 The Swedish Cancer Register 
The Swedish Cancer Register was founded in 1958 to follow the incidence and changes over 
time for cancer diseases. All health care providers are obliged by law to report cancer cases 
among registered individuals in Sweden to the authority. The register is therefore nationwide 
and in general, more than 99% of all cancer cases are reported, albeit with some delay. Since 
the 1980s, the reports from health care providers first go to one of six regional cancer centers 
who code, register and control the quality before reporting their statistics annually to the 
Swedish Cancer Register. The most recent study of the completeness of the Swedish Cancer 
Register reported a 90% coverage of digestive organ cancers compared to the hospital 
discharge records in 1998 (93). Based on the hospital journals, the study found that 
underreporting was not random. Instead, underreporting was more likely to occur if there was 
a missing pathology verification, if the patient was of older age, and if health care providers 
were not part of University hospitals. Still, the authors concluded that the completeness of the 
Swedish Cancer Register was comparable to other high-quality Northern European cancer 
registers and that the underreporting should not have major influence on most epidemiological 
studies (93).  
In the Swedish Cancer Register, one can find detailed information, including the personal 
identity number, the date of cancer diagnosis, sex and age at diagnosis, the location of the 
cancer (according to the International Classification of Diseases (ICD) systems from 1958 and 
onwards), morphology (according to SNOMED II), histopathological diagnosis (PAD) and 
TNM-status (and if it is clinical or pathological staging) of the tumor at diagnosis. The TNM-
status registration began in 2004 and the completeness is unfortunately poor. Moreover, high-
grade dysplasia or cancer in situ and pathological grade of the tumor are generally not 
registered. 
4.2.1.2.2 The Cause of Death Register 
The Cause of Death Register in Sweden holds electronic records from 1952 to 2012 of deaths 
and underlying causes of death among those registered in Sweden (94). From 2012 and 
onwards it includes all deaths, no matter if the individual was registered in Sweden or not (94). 
The completeness of death reports is considered full since a death certificate is mandatory for 
a burial to take place (94). Until 1991 a report of the cause of death was also mandated by law 
for a burial (94). This requirement was abolished in 1991, which meant from 1991 until 1997, 
only those reports with a cause of death were included in the register (94). After 1997, all death 
reports, even those with a missing report of the cause of death were included in the register 
(94). The cause of death is coded according to the international ICD system, unlike the rest of 
the health care system that uses the Swedish version of the ICD coding system (94).  
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The quality of the cause of death reports is influenced by the reporting physician’s knowledge 
of the patient history and understanding of the logic underlying the report. The means and aids 
in the reporting system and the measures undertaken by responsible authorities to control the 
quality and correctness of the register are also important. The most recent assessment of the 
register among a random sample of 1,094 deaths, reported a 77% match between cause of death 
reports and the cause expected from hospital discharge records (95). For malignant neoplasm 
cases, there was a 90% match, while COPD and other pulmonary diseases had the lowest match 
of 47% (95).  
Overall, considering the high degree of completeness and high quality of the reports of 
underlying cause of death, the temporal changes, the heterogeneity between practitioners and 
loss of underlying cause of death reports should not have a major impact on the quality of 
malignant cases in the Cause of Death Register. 
4.2.1.2.3 The National Patient Register 
The National Patient Register consists of the National Inpatient Register (also called the 
Hospital Discharge Register) and the Outpatient Register. The National Inpatient Register was 
initiated in 1964 but full-scale registrations, i.e., reaching nationwide coverage, were not 
achieved until 1987. From 2001 and onwards, specialized outpatient visits are included in the 
National Patient Register. According to a review of validation studies concerning the National 
Inpatient Register, the positive predictive value (PPV) was found to be 85-95% for most 
evaluated diagnoses (96). The sensitivity for COPD was in the lower range: 27% in one study 
(96).  
The National Patient Register does not seem to have been validated for the diagnosis of 
alcoholism, but it is likely that the PPV is low considering that the validity for alcoholism in 
the Cause of Death Register was low in a previous study (97). We could not find a validation 
of esophagectomy, gastrectomy or anti-reflux surgery in the National Patient Register, but it 
could be similar to other surgical procedures such as amputations, appendectomies and surgery 
of inguinal hernia with a PPV of over 90% in previous validation studies (96). 
A major limitation of the National Patient Register is that primary health care patients and 
patients not treated by physicians are not included in the register. As a consequence, certain 
diagnoses not requiring specialized health care or certain procedures such as endoscopy may 
be incomplete.  
4.2.1.2.4 The Prescribed Drug Register 
The Prescribed Drug Register began in July 2005 and includes all prescribed drugs dispensed 
at pharmacies in Sweden since then. It is updated monthly. Since it is an automated 
administrative register regulated by law, the reporting is nationwide and the loss of data is very 
low. However, there are many challenges to be aware of when using this register. The first 
thing to keep in mind is that drugs administered within the health care system, such as 
ambulatory care, inpatient and outpatient care, day-care, elderly care (except ApoDos which is 
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delivered by pharmacies) and so on are not registered here. Since there are regional health care 
system differences, some drugs may be provided by the care-giver in some regions and 
dispensed at the patient’s own expense in other regions. Furthermore, over-the-counter drugs 
and drugs prescribed but never collected at a pharmacy, do not enter the register. Some drugs, 
such as pain-killers or anti-reflux medicines can both be prescribed and bought over-the-
counter.  
In an attempt to standardize the definition of drug dose, the World Health Organization (WHO) 
provides the Defined Daily Dose (DDD) system. Certain drugs such as chemotherapy do not 
have a DDD. 
Another major limitation to be aware of is that the dispensed drugs are not the same as the 
drugs taken by the patient. A previous validation study of asthmatic adolescents (11-14 years 
of age) found that 30% of patients with parent-reported use of asthma medications did not have 
dispensed asthma drugs during the preceding 18 months (98). Moreover, even if the drug was 
taken by the patient, it is no guarantee that the drug dose corresponds to the drug exposure in 
that individual. For instance, inhalation asthma medications are frequently administered with 
inadequate technique, resulting in an under-exposure of the medicine.  
4.2.1.2.5 The Total Population Register and LISA 
The Total Population Register (99) and LISA (100) from Statistics Sweden complement many 
medical epidemiology studies with demographical data on sex, date of birth, country of birth, 
immigration and emigration as well as socioeconomic information such as civil status, 
education, income, occupation, use of social benefits, etc. The demographical data is nearly 
complete, while socioeconomic variables are less complete. Older patients generally have more 
missing data on education, occupation and use of social benefits typically due to retirement. 
Other limitations are the inadequate registration of educational level of immigrants, and that 
co-habitation—which is more common than marriage—is not included in the variable civil 
status. For migration data to be registered, the individual has to report this to the Swedish tax 
authority (Skatteverket). Some, especially those with shorter periods of emigration, may not 
register immigration/emigration status.  
4.2.1.2.6 The Multi-Generation Register 
The Multi-Generation Register is a part of the Total Population Register system and includes 
individuals who were registered in Sweden any time from 1961 and onwards and who were 
born 1932 or later. These individuals constitute the “index persons”. For every index person 
there is a link to the biological or adoptive parents. The register is updated annually with new 
“index persons” that have immigrated or been born. For more information please read the 
information available in the report about the Multi-Generation Register from Statistics Sweden 
in 2016 (www.scb.se).  
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4.2.1.2.7 The National Quality Register for Esophageal and Gastric Cancer (NREV) 
This National Quality Register was founded in 2006 and is maintained by one of the Regional 
Cancer Centers. The primary aim of the register is to provide comparisons of indicators of 
quality of care and outcomes in Sweden to enable improvements. The register is however 
increasingly used for research purposes as well. In 2018, the completeness of reported 
esophageal cancer patients and gastric cancer patients was 95% and 91%, respectively, 
compared to the Swedish Cancer Register. The register comprises records of incident 
esophageal and gastric cancer patients, with information on high-grade dysplasia/cancer in situ. 
Patients diagnosed and examined outside the country, but treated in Sweden, are also included 
in the register. NREV initially only collected data on surgical procedures. Since 2008, the 
register also began collecting data on oncological treatments (NREV Annual report 2018 
accessed from www.cancercentrum.se). The mean lead-time from diagnosis to treatment 
(oncological or surgical) was 46 days for esophageal cancer and 45 days for gastric cancer in 
2017-2018. At diagnosis, the treatment intention—which can be either curative, palliative or 
no tumor-specific treatment—is recorded. Health care providers generally aim for 40% of all 
gastroesophageal cancer patients to receive curative treatment, but what this treatment consists 
of varies between the regions due to currently unknown reasons. In Stockholm during 2017 to 
2018, for patients who had a curative treatment intention at diagnosis, the distribution of the 
planned therapeutic strategy was as follows: about half of the patients were to receive a 
combination of curative resection and oncological treatment, about a third were to receive only 
curative resection, and the rest were to receive only oncological treatment. The resectability, 
i.e. the proportion of patients planned for resection that actually received the treatment, has 
varied between 80-90% for the whole country since the start of the register. Palliative treatment 
or no tumor-specific treatment intention at diagnosis was recorded for 37% of the esophageal 
cancer patients and 32% of gastric cancer patients; the majority in this patient group received 
only oncological treatment. 
The overall 5-year survival rate recorded in NREV is surprisingly similar for esophageal and 
gastric cancer patients. In the most recent annual report from NREV the overall 5-year survival 
rate was 15%. Among those with curative resection the 5 year-survival rate was 40%. The 
survival is strongly dependent on the tumor stage at diagnosis. Furthermore, the mode of 
palliative treatment was also associated with different survival rates. 
NREV is a powerful register to follow, compare and improve the health care practices for 
gastroesophageal cancer patients and provides many research opportunities in this context. The 
register is very extensive and many variables of interest for epidemiological studies can be 
found in this register. Many of the treatment-related variables for gastroesophageal cancer 
patients only exist in this register besides the medical charts, or have better completeness than 
other registers, such as TNM-stage. On the other hand, the completeness of some variables is 
not yet high enough for research purposes, such as smoking and the choice of oncological 
treatment. Other limitations with the register is the relatively short duration since the start in 
2006 and that several variables have been included only recently, making the follow-up time 
even shorter. Inclusion of information about precursor lesions from the Correa cascade or 
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Barrett’s esophagus would have been useful, but are probably not feasible considering the way 
data are currently collected. With that said, NREV is an extraordinary and valuable source for 
research about gastroesophageal cancers in Sweden. 
4.2.1.3 Regional or local registers 
4.2.1.3.1 The electronic medical records system TakeCare 
TakeCare is the current electronic medical records system in Stockholm-Gotland and contains 
all medical charts written in the region, as well as reports on all examinations (blood samples, 
pathology/cytology samples, x-ray, etc.) and all drugs and medical devices ordered or 
prescribed in the region. Inpatient and outpatient chemotherapy orders, dose and administration 
details (registered by the nurse) can be retrieved from this system.  
The limitations regarding daily routine work, and research purposes for that part, are 
unfortunately exhausting. The main issues with using TakeCare for research is the structure of 
the system, redundant and false information, the lack of validation and the extensive manual 
work that has to be spent to retrieve reliable data and clean it for use in research. Furthermore, 
some clinics, such as the intensive care unit, use other parallel or add-on software for 
prescribing and/or documentation. 
4.2.1.3.2 The VAL-database 
The VAL-database is an administrative individual-level register for the Stockholm County 
Council that follows all health care delivered to the inhabitants of the region for the purposes 
of  planning and following up the need, quality and efficiency of the health care in the region. 
The database started with only inpatient care, but has since grown to encompass a number of 
other administrative registers. Since 1995, it also contains outpatient data including primary 
health care data. The VAL-database can be used to retrieve additional information about all 
drug prescriptions in the region and drug requisitions from health care providers. It also 
contains some information about over-the-counter drugs, though not all pharmacies report this 
data. The drug information in the VAL-database comes from several different sources, 
including the service for pharmacies (ASAB), pharmacies and drug providers. The VAL-
database does not register health care given by providers without a contract with the Stockholm 
County Council. 
The added value of the VAL-database information on drugs compared to the Prescribed Drug 
Register, is that VAL also includes both inpatient (hospital) and outpatient (primary health 
care) drug prescriptions and drug requisitions which might not be registered in the Prescribed 
Drug Register. 
4.2.1.3.3 The SALT register 
The SALT register was a nationwide inpatient drug register that was active during 2008 to 
2014, and was upheld by Apoteket AB, a state-owned pharmacy. Following the deregulation 
of the pharmacy market, the SALT register ceased registration of new data. The SALT register 
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contains information about the chemotherapy dose prepared for inpatient care at the individual 
level and the details of delivery to the health care provider. 
4.2.2 Case-control study 
A case-control study was carried out from 2010 to 2014 by our group in collaboration with 
colleagues at Fudan University and Shandong University in China for the purpose of studying 
several suspected risk factors for esophageal squamous cell carcinoma and gastric cancer. The 
location was chosen due to the high incidence of ESCC, with a raw incidence rate as high as 
60/100,000 person-years (101). Given that Taixing, a city in China, has a population of 1.2 
million, we estimated an annual total number of 680 eligible incident ESCC cases (95% of total 
number, after excluding those older than 79 years, and those residing in the area less than 10 
years). A previous pilot study indicated that 90% of ESCC cases could be identified prior to 
treatment, and that 90% of these were willing to join the study.  
The rationale for using a case-control study design in this setting is mainly that a case-control 
study is more efficient than a cohort study in the context of studying an exposure with a long 
latency period such as gastric atrophy, and a cancer disease with low incidence in the 
population. The drawback is that the odds ratios estimate derived from the logistic regression 
analysis in this study is not a direct measure of the relative risk even if it is a close 
approximation of the relative risk derived from a cohort study, in our context. Furthermore, 
when designing case-control studies, one needs to carefully consider and plan for how to reduce 
the effects of random and systematic errors. 
To begin with, we tried to reduce the effect of random error by having a large sample size. 
Previous studies reported a prevalence of 15% for gastric atrophy. Based on different 
assumptions where the prevalence of gastric atrophy was 10%, 15% and 20% with an alpha 
level of 5%, we estimated that to detect an odds ratio of 1.5, the recruitment of 1100 cases and 
1600 controls  would be required to provide the statistical power of 0.92, 0.98 and 0.99, 
respectively. Furthermore, assuming a 15% prevalence of corpus atrophy and a dichotomized 
variable of decayed, missing or filled teeth (our main variable for poor oral health), the 
estimated statistical power to detect a gamma for additive interaction of 2 would be 0.85, under 
the assumption that RR01 and RR10 are equal to 2. 
Cases were enrolled through a rapid case ascertainment system established at the four largest 
hospitals in the region where patients undergoing endoscopy were invited to participate in the 
study. We also complemented with cases from the local Cancer Registry. The controls were 
sex- and age-matched (by 5-years intervals) according to the Total Population Register and 
invited to participate in the study every twelve months. The collected data underwent 
continuous quality controls, and dialogue was kept with our collaborators to correct errors 
during the data collection.  
A field station was established and local staff were trained to perform interviews of cases and 
healthy controls and register the answers in a validated electronic questionnaire. Blood samples 
were collected and analyzed for Pepsinogen I and II as biomarkers for gastric atrophy, and H. 
pylori serology.  
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ELISA of Pepsinogen I and II were performed at Qilu Hospital of Shandong University, China 
with Pepsinogen I and II Kits from Biohit HealthCare (Helsinki, Finland). The inter-assay 
coefficients of variation were 11.3 % and 14.9 %, respectively. Immunoblotting with IgG 
antibodies directed against H. pylori were quantified using Helicobacter pylori IgG Antibody 
Detection Kit from Syno Gene Digital Technology, Taizhou, China. 
Study III in this thesis was a sub study of the above mentioned case-control study and was 
focused on the risk for esophageal squamous cell carcinoma associated with gastric atrophy 
and the interaction with poor oral health. The gold standard method for clinical diagnosis of 
gastric atrophy is endoscopy. It should be noted that gastric atrophy has a patchy distribution, 
which may result in atrophic sites being missed at endoscopy. Gastric atrophy, however, affects 
the pepsinogen producing glands and is therefore associated with low serum pepsinogen I level. 
Furthermore, collecting serum samples is less invasive and the risk of complications is 
considerably lower than with endoscopy. These concerns, paired with the ethical and practical 
aspects in a study with such a large sample size, led us to choose serum samples instead of 
endoscopy as the means of measuring the exposure for gastric atrophy. We used the pepsinogen 
cut-off values to determine gastric atrophy based on a previous validation study from our group 
in a high-risk population in northern Iran. It would have been ideal to perform a validation 
study of the cut-off value for pepsinogen in the Taixing population as well, but unfortunately 
this was not within the scope of this study. Other than this limitation, we made considerable 
efforts to decrease the risk for systematic errors such as bias, confounding and misclassification 
of the outcome and exposures which are described in paper III. 
4.3 STATISTICAL METHODS 
4.3.1 Measurements of risk, relative risk, and underlying assumptions 
4.3.1.1 Incidence rate and cumulative risk 
Crude incidence rates were calculated by dividing the number of observed cases with the 
accumulated person-years for our different exposure groups. We used this disease frequency 
estimate in paper I and II for our exposure groups that consisted of the first record of a gastric 
or esophageal biopsy taken at endoscopy and diagnosed with histopathology. Individuals in 
each exposure group could have several findings at the same endoscopic examination. We 
therefore chose to use the most severe finding to categorize each patient. The rationale for this 
categorization was to focus on the prognostic value of the first biopsy which we believe is 
mostly affected by the most severe finding, though other cut-off points as specified on a 
statistical, clinical or operational basis could also have been an alternative (102). We also chose 
to only count person-time until the first diagnosis of gastroesophageal cancer. Since a majority 
of gastroesophageal cancers are diagnosed in an advanced stage, many patients are likely to 
have lived with their cancer for some time before the diagnosis. The incidence rates for cancer 
in this study thus reflect the time until diagnosis, and not the actual occurrence of disease. As 
these cancers progress rapidly, the time lapse between actual occurrence of the disease and the 
subsequent diagnosis should not be a major issue.  
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Cumulative incidence rate was calculated using the Nelson-Aalen estimator in paper I. Since 
the Nelson-Aalen estimator is non-parametric, it can be used to calculate the cumulative 
incidence rate function of right-censored and left truncated survival data as in our study. The 
estimator can also be used in several other situations such as counting relative mortality, 
cumulative infection rate or Markovian multi-state models (103). On the other hand, the 
Kaplan-Meier estimator can only be used for survival data. We used the Kaplan-Meier 
estimator in paper IV to illustrate cumulative risk by different exposures groups. 
4.3.1.2 Standardized incidence ratio (SIR) 
For the purpose of calculating standardized incidence ratios (SIRs) in papers I and II we 
retrieved incidence rates for gastroesophageal cancers stratified by sex and age group (5-year 
intervals) for the general population from the Swedish Cancer Register. The Swedish Cancer 
Register encompasses all primary tumors (if the primary tumor is unknown, metastases can be 
reported). All in all, the Swedish Cancer Register contains records for about 3 million tumors 
from 2.4 million individuals residing in Sweden during the period of 1958-2016. 
Standardized incidence ratios (SIRs) were calculated by dividing the observed number of 
cancer cases in each exposure group by the expected number. The expected number was 
derived by multiplying the incidence rate for the general population with the sum of person-
years for each exposure group. Since the incidence rate for the general population is including 
repeated gastroesophageal cancers in the same individual (although this occurs rarely), the 
expected number in our SIR calculation may be overestimated, resulting in an underestimation 
of the relative risk. This should, however, not have a major impact since the survival is very 
poor for gastroesophageal cancer patients and the proportion of patients with repeated 
gastroesophageal cancer in the cancer register is low (< 1% in our dataset). Another aspect of 
the incidence rate from the Swedish Cancer Register is that cancer cases diagnosed post-
mortem through autopsy are also recorded. We did not include those cases in our study 
population and therefore the SIR may be a slight underestimation. Even so, this should not have 
a major influence given the low proportion (about 2.5% of the cancer cases in our study 
population were identified first at autopsy) and that autopsies have become less and less 
frequent with time. 
4.3.1.3 Logistic regression and interactions 
We used logistic regression to calculate odds ratios (ORs). The rationale for using logistic 
regression instead of linear regression was that the outcome was binary and that logistic 
regression is more convenient for handling multivariate models. Although we frequency-
matched the controls on group level by sex and age-group (5-year intervals), we used 
unconditional logistic regression. This was decided since the matching was done at such an 
aggregated level that standard analysis adjustment for the matching factors was the most 
appropriate method to use, which is in line with the reasoning in a previous article on matched 
logistic regression analysis (104). Some of the assumptions underlying a logistic regression 
model is that the independent variables should not correlate with each other. Another 
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assumption is that the independent variables and the dependent variable are linearly related on 
the log odds scale (105).  
To test for multiplicative effects between our main exposure of gastric atrophy together with 
poor health, we included an interaction term in our multivariate logistic regression model.  
Additive interaction was tested using the following measures: relative excess risk due to 
interaction (RERIOR), synergy index (S), and attributable fraction due to interaction also called 
attributable proportion (AP). The measures for additive or so called biologic interaction rely 
on a model by Rothman (106) for causal mechanisms and assume no confounding. Based on 
this model, Rothman argues that biologic interaction should be assessed as departure from 
additivity of effect and not multiplicativity.  
As explained by Knol et al the RERI is “part of the total effect that is due to interaction”, S is 
the “ratio between combined effect and individual effects”, and AP is the “proportion of the 
combined effect that is due to interaction” (107). The equations for the additive interaction tests 
are described in previous articles on the subject (107, 108).  
4.3.1.4 Cox regression model 
Hazard ratios (HRs) were estimated by using Cox proportional hazards regression models. The 
Cox regression model is called a semi-parametric model because it does not make a parametric 
assumption about the baseline hazard function but instead, assumes that the hazard rate ratio is 
constant. The advantage of using Cox regression instead of a parametric model was that we did 
not know the underlying distribution of the hazard for death or disease outcome and did not 
have a need to estimate it. If it would have been important to estimate the baseline hazard rate, 
we could have employed a flexible parametric model. The proportional hazards assumption in 
our studies was checked using Schoenfeld residuals and significance tests. When there was 
indication of violation of the proportional hazards assumption, we stratified the model by the 
co-variate in question. Another way of dealing with non-proportional hazards is to use the 
interval Poisson model by defining short intervals of time that includes an interaction term with 
time. The interval Poisson regression model differs from the Cox regression model in that the 
Poisson model assumes a constant hazard within the time intervals. However, in a scenario 
where there are shorter intervals of a couple of months at a time, the Poisson model yields 
similar estimates to that from a Cox model. Alternatively, we could have introduced an 
interaction term with time for the non-proportional co-variate. Given that we did not need to 
estimate the effect of the non-proportional co-variates, model stratification was ultimately more 
efficient and the method of choice for dealing with non-proportional hazards.  
4.3.2 Random and systematic error 
4.3.2.1 Random error 
Random error refers to a random deviation from the true observation and can push the observed 
value away from the true value in any direction. Random error affects the variability but not 
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the average. Random error can be due to sampling error, or non-sampling error. Sampling error 
occurs due to taking a sample and not studying the entire source population and is usually 
influenced by the sample size and the variation of the variable of interest in the source 
population. Two widely used methods for appraising the impact of sampling error are 
hypothesis testing and estimating the confidence interval. An appropriate sample size can help 
decrease the impact of sampling error on study estimates. To arrive at a suitable sample size 
when planning a study a power calculation can be employed. On the other hand, random error 
can also occur due to non-sampling error, such as measurement error which can be due to 
difficulties measuring the variable of interest or variation with time. It is more difficult to assess 
the impact of non-sampling random errors than sampling errors and requires careful 
considerations when planning and conducting the study regarding the measurement methods 
and how they are executed, reported, processed and analyzed. 
In study I and II we virtually used the entire source population in Sweden during the study 
period and the number of outcome is reasonably large, so the sampling error should be small 
but non-sampling errors are likely due to measurement error and variations with time since we 
could not influence the collection of retrospective data. In study III we tried to reduce the 
impact of sampling error by a prior power calculation and reaching an appropriate sample size. 
However, random measurement error is still likely. Study IV was hypothesis-generating and 
not experimental since we lacked prior knowledge about the prevalence of exposure to each 
specific chemotherapy regimen and the effect size we could expect. The impact of random 
sampling error is considerable, but the measurement error should be low due to high 
completeness of the registers used.   
4.3.2.2 Systematic error 
Systematic error, or bias, influences the estimate in a predicable direction, either under- or 
overestimation of the “true” population estimate. To reduce systematic error careful attention 
needs to be paid to the study design, gathering and analysis of the data. There are numerous 
sources of bias and each study requires prior planning to reduce the specific biases for each 
situation, as we described these in each paper I-IV. Below is a brief description followed by 
how we tried to decrease the major sources of bias. The goal with reducing systematic error is 
to achieve accurate estimates, close to the “true” population value. 
4.3.2.2.1 Selection bias 
Selection bias is when the study sample is not representative of the source or target population. 
In our register-based cohort studies (study I-II), selection bias is mainly due to reverse causation 
or loss of follow up. To reduce selection bias in study I and II we excluded the first two years 
of follow-up. The high-quality registers guaranteed that loss to follow-up is negligible. In study 
III, we tried to decrease selection bias by inviting all potential cases at the major hospitals in 
the region to participate. We also complemented with missing cases from the local Cancer 
register. Non-respondent cases and controls were not statistically different from respondents 
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regarding age at interview and sex, but we could not assess differences regarding other 
sociodemographic or tumor-related variables.  
4.3.2.2.2 Information bias 
Information bias is concerned with systematic misclassification of the exposure or outcome. 
We believe that the risk for differential misclassification of the exposure should be low in study 
I and II. However, some histopathology diagnoses are known to have a high inter-observer 
variability so gastric atrophy and esophageal metaplasia with low-grade dysplasia are more 
prone to misclassification compared to intestinal metaplasia or high-grade dysplasia. In study 
III we tried to assess the impact of misclassification of the exposure by employing other cut-
off criteria for Pepsinogen I, II and their ratio, resulting in a similar magnitude of association, 
although not always statistically significant. Further, in study III, the histopathology samples 
of suspected cases were carefully reviewed by one pathologist to reduce the risk of 
misclassification of the outcome. Differential misclassification of the exposure or outcome in 
study IV should not be a major issue given the high-quality registers employed for data 
collection. 
4.3.2.2.3 Confounding 
A confounding factor is related to both the exposure and outcome and explains all or some of 
the estimated association between the exposure and the outcome. We have accounted for the 
potential confounding factors we considered in the separate papers I-IV. In addition to adjusting 
for potential confounding factors in our multivariate models we also frequency matched cases 
and controls by age (5-year intervals) and sex in study III and restricted or stratified the study 
sample to handle potential confounding factors in study I-IV. Despite our best efforts to adjust 
for potential confounding factors, there is always the risk for residual unmeasured confounding. 
In study I residual confounding could be life-style factors that we did not control for; in study 
II it could be some currently unknown but widespread environmental exposure; in study III it 
could be the socioeconomic status and other unknown factors; and in study IV it could be 
confounding by indication.  
4.4 RESEARCH ETHICS 
4.4.1 Ethical principles and approvals 
All studies were conducted according to the WMA Declaration of Helsinki - Ethical Principles 
for Medical Research Involving Human Subjects and were approved by the regional ethics 
committee in Stockholm or the Swedish Ethical Review Authority according to the following: 
study I (Dnr 2010/819-31-3, 2013/1244-32, 2015/1469-32, 2016/247-32, 2016/525-32), study 
II (2014/1287-314, 2020-00382), study III (Dnr 2018/357-31, and the Institutional Review 
Board of School of Life Sciences, Fudan University), and study IV (2012/1236-31-4, 
2012/1726-32, 2014/849-32, 2017/597-32). 
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4.4.2 Ethical considerations 
Ethical considerations specific for epidemiological studies generally concern the interests of 
the society versus the interest of the individual. It is often assumed that what lies in the interest 
of society is also beneficiary for the individual. Many ethical dilemmas however arise when 
these interests are mutually exclusive. In extreme cases, the need of the society to identify or 
limit a disease might impose a threat to the integrity, well-being or liberty of the individual. It 
is the responsibility of the researcher to ensure that the research they conduct is ethically and 
morally justified. Briefly, research ethics encompasses four main aspects with regards to the 
research subjects involved: autonomy, non-maleficence, beneficence and justice.  
The respect for autonomy comprehends preserving human dignity, human rights and freedoms. 
Further, it requires accessible and objective information about the study details, and that all 
participation in research is voluntary, where individuals are allowed to withdraw at any time. 
This is usually ensured by written informed consent.  In some register-based epidemiological 
studies informed consent can be difficult to achieve and might inflict more harm than benefit 
to the individual, but the respect for the autonomy can still be uphold if individuals are sharing 
their individual data voluntarily or can opt-out from participation in health-care registers or 
administrative registers. We could not obtain informed consent from all the study participants 
in our register-based studies I, II and IV but we believe the benefits outweigh the risks in these 
studies. In study III participation was voluntary and patients were only included if they gave 
informed consent.  
The next aspect is non-maleficence and many times entails avoiding unnecessary invasive or 
unsafe methods of diagnosis or interventions. In study III this was one of the reasons we chose 
to use the less invasive method of “serological biopsy” by measuring Pepsinogen I and II in 
blood samples instead of performing the more invasive method of diagnosis through endoscopy 
and histopathology, especially for controls. We also handled sensitive data with great care in 
all studies to ensure that it was only accessible by the necessary researchers involved in the 
study. 
We aimed to design and conduct our studies so that they would be beneficial to either the study 
participants themselves or future patients. And lastly, the aspect of justice in our studies 
concerned studying gastroesophageal cancers that are much less studied but more fatal than 
more common cancers such as breast, lung or prostate cancer and furthermore including patient 
groups that are otherwise often excluded or disregarded from clinical trials such as patients 
with advanced tumor stage or palliative treatment in study IV.   
Besides the ethical considerations in relation to the study participants there are numerous 
other ethical dilemmas in research ethics concerning undeclared conflicts of interest, 
plagiarism, authorship conflicts and other forms of scientific misbehavior. It is the interest of 
the research community as well the society to keep these ethical issues at a minimum since it 
undermines the trust in the scientific community.  
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5 MAIN RESULTS  
5.1 HIGH-RISK INDIVIDUALS FOR GASTROESOPHAGEAL CANCER 
5.1.1 Family history of gastric mucosal changes 
Our main finding in paper I showed that being a first-degree relative (parent, sibling or child) 
to a person with a gastric mucosal lesion was associated with an increased risk for gastric 
cancer, and more so for gastric non-cardia cancer than cardia cancer (Table 1) (77). The excess 
risk for gastric non-cardia cancer increased incrementally with the severity of the gastric 
mucosal lesion (except for “other, unspecified changes”), and the increase of excess risk was 
statistically significant. The excess risk for gastric non-cardia cancer was 30% among 
individuals with a family history of gastritis, and 50-60% among patients with atrophic 
gastritis, intestinal metaplasia or dysplasia compared to the general Swedish population.  
Table 1. Standardized incidence ratios (SIRs) with 95% confidence intervals (CIs) for relatives of biopsy 
patients, grouped by the mucosal changes of index biopsy patient 
Family history of 
gastric mucosal 
changes* 
All gastric cancer Non-cardia gastric cancer Cardia gastric cancer 
Obs Crude 
IR ± 
SIR§ 
(95% CI) 
Obs Crude 
IR ± 
SIR§ 
(95% CI) 
Obs Crude 
IR ± 
SIR§ 
(95% CI) 
Normal/minor changes 357 10.2 
1.01  
(0.94-1.12) 
268 7.7 
1.00  
(0.88-1.13) 
89 2.5 
1.04  
(0.83-1.28) 
Gastritis 592 12.0 
1.24  
(1.15-1.35) 
475 9.6 
1.31  
(1.19-1.43) 
117 2.4 
1.04  
(0.86-1.25) 
Other unspecified 
changes 
145 11.6 
1.09  
(0.92-1.28) 
99 7.9 
0.99  
(0.80-1.20) 
46 3.7 
1.40  
(1.02-1.86) 
Atrophic gastritis 47 13.2 
1.31  
(0.96-1.75) 
40 11.2 
1.47  
(1.05-2.01) 
7 2.0 
0.81  
(0.33-1.67) 
Intestinal metaplasia 27 12.7 
1.28  
(0.84-1.86) 
25 11.7 
1.59  
(1.03-2.35) 
2 1.0 
0.37  
(0.04-1.33) 
Dysplasia 29 13.1 
1.22  
(0.82-1.75) 
28 12.6 
1.53  
(1.02-2.21) 
1 0.5 
0.18  
(0.00-1.01) 
Gastric cancer 105 22.7 
2.17  
(1.78-2.63) 
85 18.4 
2.33  
(1.86-2.89) 
20 4.3 
1.68  
(1.03-2.60) 
Chi2 test for trend€   p=0.0028   p=0.0018   p=0.2818 
Obs, observed cases. IR, Incidence Rate. 
* Defined by the gastric cancer family history known at baseline (Cancer register) or the mucosal change diagnosis of the 
index biopsy patient 
± Per 100 000 person-years 
§ Observed to expected number of GC cases, based on age- (5-year strata), calendar year- (5-year strata) and sex-specific 
incidence rates in the total Swedish population. Ninety-five percent CIs of SIRs were calculated by assuming that observed 
cancer occurrence followed a Poisson distribution. 
€ Excluded the 'other unspecified changes' category 
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An interesting finding was that having a sibling with gastric lesions had a higher excess risk 
than having an affected parent or children. Those having siblings afflicted with severe gastric 
mucosal lesions (atrophic gastritis, intestinal metaplasia or dysplasia) had a more than 2-fold 
risk (HR ranged from 2.3 to 2.7) for gastric non-cardia cancer compared to those having a 
sibling with normal or minor mucosal changes (Table 2).  
Table 2. Hazard ratios (HRs) and 95 % confidence intervals (CIs) for non-cardia gastric cancer among relatives 
of biopsy patients with different pathological changes in the stomach compared to relatives of patients with 
normal gastric mucosa, by classes of first-degree relatives  
Family history of 
gastric mucosal 
changes 
Parents (n=195 704) Siblings (n=283 371) Children (n=424 262) 
Number 
of cases 
HRs and 95 % 
CIs* 
Number 
of cases 
HRs and 95 % 
CIs* 
Number 
of cases 
HRs and 95 % 
CIs* 
Normal/minor changes 204 
 
Reference 55 
 
Reference 9 
 
Reference 
Gastritis 267 
 
1.16 (0.96-1.39) 184 
 
1.70 (1.25-2.31) 24 
 
1.26 (0.58-2.74) 
Other unspecified 
changes 
52 
 
0.91 (0.67-1.24) 46 
 
1.70 (1.15-2.52) 1 
 
0.19 (0.02-1.50) 
Atrophic gastritis 20 
 
1.17 (0.73-1.85) 20 
 
2.48 (1.48-4.15) 0 
 
- 
Intestinal metaplasia 10 
 
1.43 (0.75-2.71) 13 
 
2.71 (1.47-5.00) 2 
 
1.72 (0.36-8.14) 
Dysplasia 11 
 
1.11 (0.60-2.05) 14 
 
2.34 (1.29-4.24) 3 
 
2.62 (0.69-9.90) 
Gastric cancer 25 
 
1.67 (1.10-2.55) 56 
 
3.83 (2.63-5.58) 4 
 
1.69 (0.52-5.55) 
* Using attained age as underlying time scale, estimated by Cox proportional hazards regression model, adjusted for sex, 
family size, year of birth, and stratified by pathology department. 
Furthermore, we discovered that the risk for gastric non-cardia cancer could be further 
increased among individuals with various gastric lesions if they also had a first-degree relative 
with a gastric lesion. The excess risks ranged from 140-280% for those with gastritis, other 
changes, severe lesions (atrophic gastritis, intestinal metaplasia, and dysplasia) and with first-
degree relatives ever diagnosed with normal/minor changes in the stomach, while the 
corresponding figures were 240% for gastritis and 580% for severe lesions among those with 
first-degree relatives ever diagnosed with a gastric severe lesion. The risks were consistently 
higher for both first-degree relatives of gastric cancer patients (Tables 1, 2) and those with 
gastric mucosal lesions who had family history of gastric cancer (Table 3) (77).  
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Table 3. Observed number, crude incidence rate of non-cardia gastric cancers (GC) and standardized incidence 
ratios (SIRs) with 95% confidence intervals (CIs) for biopsy patients, grouped by family history of gastric 
mucosal changes 
Mucosal status 
at baseline 
Exposure group Biopsy patients ( n = 240 101) 
Family history of gastric mucosal 
changes 
Obs * Crude IR ± SIR§ (95%CI) 
Normal/minor 
mucosal changes 
No/minor changes detected 66 9.9 1.13 (0.90-1-41) 
Gastritis 6 7.7 1.07 (0.39-2.33) 
AG/ IM/ dysplasia 1 5.2 0.75 (0.02-4.20) 
GC  0 0.0 - 
Gastritis No/minor changes detected 238 25.0 2.40 (2.10-2.72) 
Gastritis 25 20.0 2.08 (1.35-3.70) 
AG/ IM/ dysplasia 11 33.2 3.42 (1.71-6.12) 
GC  13 43.4 3.32 (1.77-5.68) 
Other 
unspecified 
diagnoses   
No/minor changes detected 85 31.1 2.64 (1.11-3.26 ) 
Gastritis 6 18.3 1.76 (0.65-3.83) 
AG/ IM/ dysplasia 2 21.4 2.04 (0.25-7.36) 
GC  4 37.0 2.81 (0.77-7.20) 
AG/IM/ 
dysplasia 
  
No/minor changes detected 68 64.8 3.78 (2.99-4.71) 
Gastritis 13 88.8 5.41 (2.96-9.07) 
AG/ IM/ dysplasia 4 97.1 6.83 (2.22-9.07) 
GC  5 115.4 7.92 (2.57-18.48) 
AG, atrophic gastritis; IM, intestinal metaplasia; GC, gastric cancer; Obs, observed cases; IR, Incidence Rate 
* The first two years of observation and corresponding events were excluded. 
± Per 100 000 person-years. 
§ Observed to expected number of GC cases, based on age- (5-year strata), calendar year- (5-year strata) and sex-specific 
incidence rates in the total Swedish population. Ninety-five percent CIs of SIRs were calculated by assuming that observed 
cancer occurrence followed a Poisson distribution. 
5.1.2 Pre-malignant esophageal lesions  
In paper II we demonstrated that individuals who were diagnosed with non-dysplastic intestinal 
metaplasia, at their first esophageal biopsy, had an 11-fold increased risk for esophageal 
adenocarcinoma compared to the general Swedish population (SIR 10.8; 95% CI 7.8-14.6) 
(Table 4).  
Surprisingly, the excess risk for esophageal adenocarcinoma was similar among patients with 
gastric or glandular metaplasia (SIR 11.9; 9.9-14.1) and other metaplasia types (mainly 
unspecified and squamous) (SIR 9.8; 5.5-16.2) (Table 4). 
The excess risk for esophageal adenocarcinoma was almost three times as high among 
columnar metaplasia (intestinal, gastric/glandular) patients with low-grade dysplasia as 
patients with non-dysplastic columnar metaplasia (SIR 30.9; 21.0-43.8) (Table 4).  
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Table 4. Incidence rate (IR) and standardized incidence ratio (SIR) of gastroesophageal cancers among patients 
with esophageal biopsies in Sweden 
 
 
 
Group by 
histopathology 
Esophagus Stomach 
Adenocarcinoma Squamous cell 
carcinoma 
Cardia 
adenocarcinoma 
Non-cardia 
adenocarcinoma 
Obs IR SIR  
(95%CI) 
Obs IR SIR  
(95%CI) 
Obs IR SIR 
(95%CI) 
Obs IR SIR 
(95%CI) 
Normal 
morphology 
18 0.1 1.9 
(1.1,2.9) 
14 0.1 1.6  
(0.9,2.7) 
9 0.1 1.0 
(0.4,1.8) 
23 0.1 0.8 
(0.5,1.2) 
Minor lesions             
   Minor/other 26 0.3 4.8 
(3.1,7.0) 
16 0.2 3.3 
(1.9,5.3) 
16 0.2 3.0 
(1.7,4.8) 
10 0.1 0.6 
(0.3,1.1) 
   Ulcer/ 
   hemorrhage 
28 0.4 5.0 
(3.4,7.3) 
4 0.1 0.8 
(0.2,2.1) 
13 0.2 2.3 
(1.2,4.0) 
9 0.1 0.5 
(0.2,0.9) 
     
   Inflammation/ 
   hyperplasia 
63 0.2 2.7 
(2.1,3.4) 
39 0.1 2.0 
(1.4,2.7) 
29 0.1 1.3 
(0.9,1.9) 
46 0.1 0.7 
(0.5,0.9) 
Severe lesions             
Barrett’s 
esophagus 
            
   Non-dysplastic  
   columnar   
   metaplasia 
173 0.9 11.6 
(9.9,13.4) 
12 0.1 1.1 
(0.6,1.9) 
47 0.3 3.6 
(2.6,4.8) 
26 0.1 0.8 
(0.5,1.2) 
      Intestinal   
      metaplasia 
43 0.9 10.8 
(7.8,14.6) 
3 0.1 1.1 
(0.2,3.2) 
11 0.2 3.3 
(1.7,5.9) 
8 0.2 1.1 
(0.5,2.1) 
      Gastric/ 
      glandular    
      metaplasia 
130 0.9 11.9 
(9.9,14.1) 
9 0.1 1.1 
(0.5,2.1) 
36 0.3 3.7 
(2.6,5.1) 
18 0.1 0.7 
(0.4,1.1) 
   Columnar   
   metaplasia  
   + LGD 
31 3.0 30.9 
(21.0,43.8) 
2 0.2 2.9 
(0.4,10.5) 
12 1.2 14.1 
(7.3,24.5) 
2 0.2 1.0 
(0.1,3.5) 
Other metaplasia 15 0.8 9.8 
(5.5,16.2) 
2 0.1 1.7 
(0.2,6.0) 
3 0.2 2.1 
(0.4,6.2) 
5 0.3 1.2 
(0.4,2.9) 
Obs, observed number of cancer cases; py, person-years. 
* (1/1000 py) 
Moreover, the excess risk for esophageal adenocarcinoma among non-dysplastic columnar 
metaplasia patients decreased with age at entry, follow-up duration and calendar year at entry 
(Table 5).  
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Table 5. Incidence rate (IR) and standardized incidence ratio (SIR) of esophageal or cardia adenocarcinoma among 
patients with non-dysplastic columnar metaplasia according to sex, age at entry, follow-up duration and calendar 
year at entry 
Characteristics Esophageal Adenocarcinoma  Gastric cardia adenocarcinoma 
Obs IR (1/1000 py)  
(95% CI) 
SIR 
(95% CI) 
Obs IR (1/1000 py) 
(95%CI) 
SIR 
(95% CI) 
Sex        
   Men 153 1.3 (1.1,1.6) 11.6 (9.8,13.6)  41 0.4 (0.3,0.5) 3.7 (2.7,5.0) 
   Women 20 0.3 (0.2,0.4) 11.6 (7.1,17.8)  6 0.1 (0.0,0.2) 3.0 (1.1,6.6) 
Age group at entry        
   30-49 yrs 7 0.3 (0.1,0.7) 58.6 
(23.6,120.8) 
 2 0.1 (0.0,0.4) 12.2 
(1.5,44.0) 
   50-59 yrs 22 0.6 (0.4,1.0) 20.4 
(12.8,30.9) 
 6 0.2 (0.1,0.4) 5.7 (2.1,12.4) 
   60-69 yrs 53 1.0 (0.7,1.3) 12.4 (9.3,16.2)  18 0.3 (0.2,0.5) 4.9 (2.9,7.8) 
   ≥ 70 yrs 91 1.2 (0.9,1.4) 9.6 (7.7,11.8)  21 0.3 (0.2,0.4) 2.6 (1.6,3.9) 
   P for trend   <0.01    <0.01 
Follow-up duration, 
years 
       
   0-<5 76 3.2 (2.5,4.0) 36.2 
(28.5,45.3) 
 22 0.9 (0.6,1.4) 12.2 
(7.6,18.5) 
   5-<10 55 1.0 (0.7,1.3) 11.8 (8.9,15.4)  15 0.3 (0.1,0.4) 3.7 (2.1,6.2) 
   10-<15 22 0.4 (0.2,0.5) 4.6 (2.9,7.0)  6 0.1 (0.0,0.2) 1.4 (0.5,3.1) 
   ≥ 15 20 0.4 (0.3,0.7) 5.8 (3.5,9.0)  4 0.1 (0.0,0.2) 1.3 (0.4,3.3) 
   P for trend   <0.01    <0.01 
Calendar year at entry        
   1981-1999 67 1.8 (1.4,2.3) 22.1 
(17.1,28.1) 
 16 0.4 (0.2,0.7) 5.2 (3.0,8.5) 
   2000-2006 70 0.8 (0.7,1.1) 10.6 (8.2,13.4)  16 0.2 (0.1,0.3) 2.8 (1.6,4.6) 
   2007-2016 36 0.6 (0.4,0.8) 6.8 (4.8,9.4)  15 0.2 (0.1,0.4) 3.5 (2.0, 5.8) 
   P for trend   <0.01    0.89 
Obs, observed number of cancer cases; py, person-years. 
5.1.3 Gastric atrophy 
Our case-control study in Taixing, China described in paper III, revealed that gastric atrophy 
(defined as serum pepsinogen I < 55 µg/l) was associated with a 60% increased risk for 
esophageal squamous cell carcinoma (OR 1.61; 95% CI 1.33-1.96) when fully adjusted for the 
following potential confounding factors: age (continuous), sex, education, marital status, 
occupation, family wealth score, body mass index 10 years prior to the interview, tea drinking, 
history of esophageal cancer among first-degree relatives, smoking status, alcohol drinking 
status, H. pylori serology-status, sum of missing and filled teeth, and frequency of tooth 
brushing per day (Table 6) (109). 
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Table 6. The odds ratios (ORs) and 95% confidence intervals (CI) for esophageal squamous cell carcinoma in 
association with gastric atrophy defined by PGI <55 μg/l, and H. pylori seropositivity in a case-control study, 
Taixing, China during 2010-2014. 
 
 
 
Variables 
 
Controls 
 
 
Cases 
  
Age/sex-adjustedb 
Fully-adjusted (except 
MFT and tooth 
brushing)c 
Fully-adjustedd 
Noa % Noa % OR 
95% 
CI 
P-
value 
OR 
95% 
CI 
P-
value 
OR 
95% 
CI 
P-
value 
PGI (μg l-1)     <0.01   <0.01   <0.01 
PGI ≥ 55 1592 83.3 
841 75.1 
  
1.00 Ref.  
1.00 Ref.  1.00 Ref.  
PGI < 55 
319 
 
16.7 
 
279 24.9 
1.60 
1.34, 
1.90 
 
1.63 1.35, 
1.97 
 1.61 1.33, 
1.96 
 
H. pylori  
sero-status  
    
0.22 
 
  0.21   0.25 
H. pylori -  622 32.5 340 30.3 1.00 Ref.  1.00 Ref.  1.00 Ref.  
H. pylori + 
1291 67.5 782 69.7 1.10 
0.95, 
1.29 
 
1.11 0.94, 
1.32 
 1.11 0.93, 
1.31 
 
No, number; ORs, Odds ratios; 95% CI, 95% Confidence intervals; PGI, Pepsinogen I; H. pylori, Helicobacter pylori; MFT, 
Missing and filled teeth. 
a Complete observations in the fully-adjusted model. 
b Adjusted for age (continuous) and sex. 
c Adjusted for age (continuous), sex, education, marital status, occupation, family wealth score, body mass index 10 years 
ago, tea drinking, history of esophageal cancer among first-degree relatives, smoking status, alcohol drinking status and H. 
pylori sero-status. 
d Additionally adjusted for sum of missing and filled teeth and frequency of tooth brushing per day. 
 
In paper III, we also showed an additive interaction between gastric atrophy and poor oral 
health, which was measured as number of tooth brushing per day (RERIOR 1.28; 0.39-2.18) 
(109). 
5.2 TREATMENT FACTORS ASSOCIATED WITH THE PROGNOSIS OF 
GASTROESOPHAGEAL CANCER 
5.2.1 Choice of chemotherapy 
The main findings in paper IV, based on the fully-adjusted Cox model, showed that the choice 
of cisplatin-fluorouracil versus carboplatin-fluorouracil was associated with a better survival 
among esophageal cancer patients with curative treatment intention at diagnosis (HR for death 
in the carboplatin-fluorouracil group compared to cisplatin-fluorouracil was 2.18; 95% CI 1.09-
4.37) (Table 7) (110). Among gastroesophageal junction cancer patients, however, cisplatin-
fluorouracil was associated with worse survival than fluorouracil-oxaliplatin (HR for death 
among fluorouracil-oxaliplatin compared to cisplatin-fluorouracil was 0.28; 0.08-0.96) (Table 
7). Other chemotherapy regimens as compared to the reference group of most common 
regimens that were used during the study period did not have a statistically significant influence 
on the survival of gastroesophageal cancer patients in the fully-adjusted Cox model (Table 7). 
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Table 7. Cohort size and hazard ratios for chemotherapy with curative intention within six months from 
diagnosis with cancer in the esophagus, gastroesophageal junction or stomach (n=279). 
a Adjusted for age (continuous) , sex and TNM-stage. 
b Additionally adjusted for radiotherapy, comorbidity, marital status, education, income and country of birth. 
 
6 DISCUSSION 
The goal with this thesis has been to further expand the understanding of the causes behind 
gastroesophageal cancers and inspire future research about the causal pathways of 
gastroesophageal cancers. We hope that this can ultimately pave the way for surveillance and/or 
primary prevention among high-risk individuals. In the long run, we hope that the research 
findings presented in this thesis can assist in decreasing the disease burden. There are a number 
of strategies to reduce the gastroesophageal cancer burden. To date, extensive research efforts 
have been undertaken to reduce the gastroesophageal cancer fatality by novel chemotherapies 
and/or new chemotherapy regimens in combination with radiotherapy. This is understandable 
given that these cancers are characterized by high rates of fatality. Still, to radically reduce 
gastroesophageal cancer mortality rates, it seems extraordinary changes are required, either in 
our understanding of the diseases and/or in the treatment strategies. A focus of this thesis is 
biological risk markers which will be discussed first. How do our findings relate to the etiology 
of gastroesophageal cancers?  
6.1 FROM BIOLOGICAL RISK MARKERS TO ETIOLOGY  
6.1.1 Familial clustering – is it due to shared environment or genetics? 
What good is it to know that there is familial clustering of gastric mucosal lesions that is 
associated with an increased risk for gastric non-cardia cancer? To begin with, this information 
supports the theory of a pathogenic pathway described as the Correa cascade. Secondly, it can 
be useful for specialist physicians in gastroenterology or upper GI-surgeons when deciding 
which patients to include in surveillance systems for gastric non-cardia cancer. Although the 
cost-effectiveness of surveillance of patients with family history of gastric mucosal lesions has 
Chemotherapy groups by cancer 
site 
Cohort N Adjusted HRa P-value Adjusted HRb 
P-
value 
Esophagus, N 132     
 Cisplatin-fluorouracil 85 Ref. Ref. Ref Ref. 
 Fluorouracil-oxaliplatin  23 1.53 (0.90-2.60) 0.12 1.28 (0.70-2.35) 0.43 
 Carboplatin-fluorouracil 14 2.33 (1.24-4.38) 0.01 2.18 (1.09-4.37) 0.03 
 Other chemotherapy 10 2.77 (1.34-5.73) 0.01 2.23 (1.02-4.91) 0.05 
      
Gastroesophageal junction,  N 59     
 Cisplatin-fluorouracil 34 Ref. Ref. Ref. Ref. 
 Fluorouracil-oxaliplatin 13 0.45 (0.16-1.25) 0.12 0.28 (0.08-0.96) 0.04 
 Epirubicin-oxaliplatin-capecitabine 7 0.76 (0.27-2.11) 0.60 0.34 (0.07-1.73) 0.20 
 Other chemotherapy  5 1.00 (0.25-4.06) 1.00 0.72 (0.15-3.46) 0.68 
      
Stomach,  N 88     
 Epirubicin-oxaliplatin-capecitabine 71 Ref. Ref. Ref. Ref. 
 Fluorouracil-irinotecan 8 2.64 (1.13-6.18) 0.03 2.26 (0.92-5.53) 0.07 
 Other chemotherapy 9 0.45 (0.15-1.36) 0.16 0.45 (0.14-1.40) 0.17 
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not been established, the most recent guidelines from the Swedish Society of Gastroenterology 
(2018) based on existing literature including two studies from our group (77, 111) recommends 
that “patients with extensive chronic atrophic gastritis and/or intestinal metaplasia or dysplasia 
in the gastric mucosa – and particularly if they also have heredity for gastric cancer (or severe 
pre-cancerous mucosal lesions) or belong to an ethnic group with high risk – should be included 
in endoscopic surveillance”. Thirdly, in addition to other established risk factors such as male 
sex, smoking and H. pylori infection among others, the factor of familial clustering could be 
useful for primary health care physicians who need to make a decision on which patients to 
investigate further for non-cardia gastric cancer.  
An examination of the relative contribution of environmental or genetic factors in the causation 
of sporadic gastric cancers was published previously in a Nordic twin registry collaboration 
(112), where it was reported that genetic heritability accounted for 28% of the variance in 
susceptibility, shared environmental factors explained 10%, and the remaining 62% could be 
attributed to non-shared environmental factors. Although the majority of gastric cancers are 
believed to be sporadic, about 10-20% are reported to have familial clustering while a minority 
of about 2-5% have hereditary forms of the disease (113). As our study encompassed gastric 
cancers with familial clustering, it is possible that the proportion of variance in gastric cancers 
explained by genetic, shared and non-shared environmental factors may differ in our study 
population compared to that based on a study population of sporadic cases. Our study on 
familial gastric cancers could therefore, in a broader sense, help untangle the environmental-
genetic relationship among family-clustered gastric cancers.  
Our study’s findings indicated a higher risk for gastric non-cardia cancer among siblings to 
index patients with severe gastric mucosal lesions (atrophic gastritis, intestinal metaplasia and 
dysplasia) than parents or children of index patients. The analysis among children was limited 
due to very few cancer cases as gastric cancer occurring at young age is rare. Still, the higher 
elevated risk among siblings than parents, could reflect that shared early-life environmental 
factors, such as life-style, H. pylori infection or H. pylori virulence in connection with 
susceptibility genes, are more likely causal factors for the majority of family-clustered non-
cardia gastric cancer cases than hereditary dominant genes or non-shared environmental 
factors.  
In summary, our study adds additional individuals to the group of high-risk individuals for 
gastric non-cardia cancer and has made a contribution to the surveillance recommendations in 
Sweden.  
In contrast to non-cardia cancer, first-degree relatives to index patients with severe gastric 
mucosal lesions (atrophic gastritis, intestinal metaplasia and dysplasia) did not display a 
statistically significant increase in risk for gastric cardia cancer. Such a finding would support 
the hypothesis that gastric cardia cancer cases are mainly of sporadic origin, wherein 
environmental or life-style related factors are key. However, family clustering of 
gastroesophageal reflux and overweight/obesity which are associated with the risk for gastric 
cardia cancer also demonstrates possible relation with genetic and/or shared environmental 
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factors. For instance, a recent statistical modelling study suggests a total elimination of 
overweight and obesity in 2016 would reduce the number of gastric cardia cancer cases in the 
Nordic countries by 11.5% during the period of 2016-2045 (114). Similar studies could help 
reveal the relative importance of eradicating or preventing other environmental risk factors 
such as gastroesophageal reflux disease and smoking. Besides informing the general population 
about the risks associated with certain life-style factors, the health-care system has a 
responsibility to pay attention to treatment of high-risk conditions. This strategy is well 
established within the health care system. If found cost-effective, measures such as primary 
prevention of gastroesophageal cancers by treating gastroesophageal reflux disease or obesity 
could be introduced into the health-care system. Similar to the way high blood pressure is 
managed today. 
6.1.2 Gastroesophageal morphological lesions and the “point of no return” 
6.1.2.1 Gastric cancer 
The Correa cascade is the most established pathway among gastroesophageal cancers. The 
pathogenic pathway is initiated by H. pylori and followed by chronic inflammation, gastric 
atrophy, intestinal metaplasia, dysplasia and gastric non-cardia cancer (intestinal type). Two 
recent studies from our group (77, 111) support the epidemiological strength of this cascade, 
but many questions still remain unanswered regarding the etiology of non-cardia gastric cancer. 
Is it so that all cancer cases go through all stages of the Correa cascade and at the same pace, 
or can this differ between patients? What determines the progression from one lesion to 
another? Is the Correa cascade reversible and at what stages? Since most of the patients with 
changes according to the Correa cascade never progress to gastric cancer, one of the current 
challenges is to understand which patients are at high risk of progression, and how to identify 
such patients in order to offer the right patients surveillance in low-risk areas.  
Intestinal metaplasia has been suggested as the “point of no return” for gastric non-cardia 
cancer and could be a candidate condition as an impetus for starting surveillance. The reason 
is that the cancer risk associated with intestinal metaplasia is considerable. Further, most 
intervention studies suggest that H. pylori eradication therapy is not as successful for patients 
with manifested intestinal metaplasia or any of the subsequent conditions in the Correa cascade 
(115). The existence of a “point of no return” is under debate and far from established since 
there are a few reports of regression in some intestinal metaplasia patients with or without H. 
pylori eradication (115). The current controversy set aside, the concept of a “point of no return”, 
if verified, could be of great clinical value to select high-risk individuals to include in 
surveillance programs in low-risk populations of gastric cancer where population-based 
screening is not cost-effective.  
There is a need for high-quality prospective studies mapping cellular and molecular changes 
of intestinal metaplasia to understand which of these patients might progress to cancer and 
which of these are stable or might regress at follow-up. So far, a prospective study from China 
on intestinal metaplasia patients found genomic and epigenomic alterations associated with 
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progression to gastric cancer among patients with severe intestinal metaplasia (116). If 
confirmed in other populations or studies, these molecular markers could be useful for 
identifying sub-populations of intestinal metaplasia patients that would benefit from screening 
or surveillance (116). Another interesting prospective study from the Netherlands and Norway 
(n=279), of patients with previous diagnosis of atrophic gastritis, intestinal metaplasia or 
dysplasia that were surveilled for a median of 4.7 years, reported that low serum pepsinogens 
(PGI/PGII≤3) and/or advanced OLGIM stage (OLGIM stage III/IV) was associated with 
malignant progression (117). If verified, these markers could also be of use in clinical practice. 
6.1.2.2 Esophageal adenocarcinoma 
The pathway to esophageal adenocarcinoma is also believed to start with inflammatory changes 
due to chronic gastroesophageal reflux leading to Barrett’s esophagus, with the potential of 
developing into low-grade dysplasia, high-grade dysplasia and esophageal adenocarcinoma. 
There have been some recent updates regarding the esophageal adenocarcinoma risk associated 
with Barrett’s esophagus. Currently, the research on esophageal adenocarcinoma etiology is 
focused on determining the sub-populations of Barrett’s patients that are at high risk of 
malignant progression, much like for gastric non-cardia cancer.  
The risk estimates for non-dysplastic intestinal metaplasia patients in paper II are in line with 
the results from a Danish histopathology register study (118), but lower for columnar 
metaplasia patients with low-grade dysplasia than most previous studies. The latter discrepancy 
could be explained by successful preventive treatment and surveillance efforts, or an effect of 
unverified low-grade dysplasia. The inter-observer variability for low-grade dysplasia is 
considerable and verification of the diagnosis by at least one additional pathologist or with a 
follow-up biopsy is required in specialist clinics. It is common that a suspected low-grade 
dysplasia diagnosis is not verified at a second review and the diagnosis is no dysplasia or 
indefinite for dysplasia. The number of verified low-grade dysplasia diagnoses has been 
associated with an increasing risk for esophageal adenocarcinoma. Unfortunately, we could not 
assess whether the low-grade dysplasia cases in our study were verified or not. We tried to 
assess the EAC risk among low-grade dysplasia patients with repeated low-grade dysplasia 
diagnoses but there were too few patients to allow a meaningful analysis. We can therefore not 
rule out that the observed lower risk estimate for columnar metaplasia patients with low-grade 
dysplasia was due to unverified low-grade dysplasia diagnoses. 
The clinical challenge with esophageal adenocarcinoma is that the proportion of patients with 
a prior diagnosis of Barrett’s esophagus is low, only 7% in a previous observational study 
(119). It is an open question if the remaining cancer cases were also preceded by Barrett’s 
esophagus but not diagnosed due to lack of symptoms, or if there are alternative pathways to 
esophageal adenocarcinoma.  
In current health care practice in Sweden, many Barrett’s esophagus patients with low-grade 
dysplasia are surveilled; if the diagnosis is verified during follow-up, preventive treatment is 
considered. Barrett’s esophagus with low-grade dysplasia that has been verified at one or 
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several follow-up endoscopies is managed as a form of “point of no return” due to the 
significant risk increase, but much is left to learn about the etiology of this disease.  
Epidemiologic studies of the increased incidence of esophageal adenocarcinoma might help in 
generating hypotheses about the etiology. For instance, a global assessment of esophageal 
adenocarcinoma incidence suggested that some environmental exposure introduced in the 
1950s could explain the dramatic increase of esophageal adenocarcinoma (21).  
Study II contributes to the field by adding some epidemiological pieces to the esophageal 
adenocarcinoma puzzle. Our study demonstrates that the relative risk for esophageal 
adenocarcinoma is similar for those with intestinal metaplasia and those with gastric/glandular 
metaplasia. Whether gastric and glandular/cardia metaplasia is a risk factor for esophageal 
adenocarcinoma is currently under debate, where some countries include these patients in 
surveillance alongside intestinal metaplasia patients while others do not. The inconsistency is 
also seen in research, where some previous studies have included gastric metaplasia in their 
definition of Barrett’s esophagus while others did not. No previous population-based study of 
this sample size has separated these two groups and so the risk associated with gastric and 
glandular metaplasia has been unclear before. 
Furthermore, other metaplasia types were also at a corresponding level of excess risk for 
esophageal adenocarcinoma. The implications of these findings could be quite substantial due 
to the vast number of patients with columnar lined epithelium in comparison with intestinal 
metaplasia. The most recent prevalence study of the general population in Sweden reported 
that the prevalence of columnar lined epithelium was about 10% and intestinal metaplasia 1.6% 
(120). If all columnar-lined epithelium patients were to be incorporated into surveillance 
program that would stress the health-care system substantially and might not even be possible 
due to limited number of doctors who can perform endoscopy. Besides the ethical 
consideration, practical and cost-effectiveness issues might be formidable. We hope that the 
largest impact will not be on clinical surveillance practices but instead on the etiological 
research field. Adding gastric and glandular patients to the population at risk for esophageal 
adenocarcinoma might lead to new discoveries about the pathogenic pathway. Before 
considering to include gastric and glandular metaplasia patients in clinical surveillance 
programs, it would be valuable to study how often and for how long these patients need follow-
up. The results in study II study suggest that the risk elevation is substantial up to ten years 
after the initial biopsy, but how often these patients should be examined was out of the scope 
of our study. 
It was also noted that the risk for gastric cardia adenocarcinoma was elevated according to a 
similar pattern as for esophageal adenocarcinoma, but with a lower magnitude. This could be 
an indication that these cancers share common etiological pathways. It is not unreasonable 
considering that esophageal adenocarcinoma and gastric cardia cancer already share several 
“up-stream” risk factors such as gastroesophageal reflux, overweight/obesity and hiatal hernia. 
On the other hand, molecular and genetic differences are also present between esophageal 
adenocarcinoma and gastric cardia cancer, so hopefully the advent of new molecular and 
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genetic classification systems will correlate better with etiological processes, progression and 
treatment than current anatomical/histologic criteria. 
6.1.2.3 Esophageal squamous cell carcinoma 
The pathogenic pathway to esophageal squamous cell carcinoma remains largely unknown. 
Squamous dysplasia is the only established precursor lesion in high-risk areas, but studies in 
low-risk populations are limited. The results in study II showed that the relative risk was about 
twice as high for esophageal squamous cell carcinoma among patients with squamous dysplasia 
(in the group with minor/other lesions) and inflammation/hyperplasia, but no associations were 
found with the other esophageal lesions. The risk associated with inflammation and squamous 
dysplasia was low in our study population, much lower than the estimates reported in a previous 
study from Linxian, China (121); could these findings vindicate a different pathogenesis for 
esophageal squamous cell carcinoma in low-risk areas than high-risk areas?  
There are some indications supporting this theory in the previous literature. Smoking and 
alcohol consumption seem to explain a larger proportion of the ESCC cases in Western 
countries than in Asia. Drinking hot beverages and using shallow water sources have been 
reported as risk factors in high-risk areas, but probably not feasible to study due to the low 
proportion exposed in low-risk areas.  
Could gastric atrophy be a risk factor for ESCC even in low-risk areas? In study III the 
association between gastric atrophy and ESCC was confirmed in a high-risk area in China. 
Study III was however preceded by a histopathology register study in the Netherlands that also 
reported an association but could not demonstrate an increased risk with increasing severity of 
gastric atrophy. The authors of that study therefore explained the association they found with 
confounding, possibly smoking. The association was however first reported by our group in a 
study from Sweden, showing that gastric atrophy (measured by serum pepsinogen) was 
associated with an increased risk for ESCC in a study enrolling 85 incident ESCC patients and 
499 randomly selected controls (40).  
The reason for the discrepancy between the previous serology and histopathology studies could 
be due to methodological differences. The histopathological diagnosis of atrophic gastritis 
suffers from large inter-observer variation in a previous study from the Netherlands (122). 
Furthermore, 44% of the patients with atrophic gastritis had regressed at follow-up biopsy 
(122). In addition to this, the endoscopy inter-observer variation is already moderate in 
experienced endoscopists in high-risk areas (123), potentially increasing the risk for 
misclassification of the exposure. It is therefore reasonable to assume that there is a risk of 
misclassification of gastric atrophy assessed by retrospective histopathology registers. The 
serologic diagnosis of gastric atrophy in patients with already manifest ESCC however leaves 
the question open about the causal pathway between gastric atrophy and ESCC. The biological 
mechanism for this remains to be elucidated and some suggestions for future studies are listed 
in the section “Future studies” in this thesis.  
  39 
6.2 PERSONALIZED TREATMENT – BEYOND THE HYPE 
The investigation of the comparative effectiveness of chemotherapy regimens for 
gastroesophageal cancer patients in the Stockholm-Gotland area of Sweden in study IV 
revealed that the choice of cisplatin-fluorouracil was associated with better survival of 
esophageal cancer patients compared to those who were treated with carboplatin-fluorouracil, 
but worse survival in gastroesophageal junction cancer patients compared to those treated with 
fluorouracil-oxaliplatin among patients who were planned to receive curative treatment at 
diagnosis. We could not compare the relative effectiveness of the same chemotherapy regimens 
among palliative cancer patients due to different choice of chemotherapy regimens.  
How can the knowledge we acquired in study IV contribute to personalized treatment of 
gastroesophageal cancer patients?  
6.2.1.1 The influence of chemotherapy among early and late stage cancer patients 
First, the aggregated effect of chemotherapy vs. no chemotherapy in gastroesophageal cancer 
patients with early or late stage tumors in the curative and palliative treatment groups was 
explored separately. The long-term survival was better for patients without chemotherapy in 
the group with early-stage tumors in the curative treatment intention at diagnosis. The median 
time to surgery was shorter among those without chemotherapy which could partly explain this 
finding. Another explanation could be confounding by indication; patients without a need for 
chemotherapy might have had more favorable patient and/or tumor characteristics such as 
better performance status, younger age, a favorable size and/or location of the tumor. Patients 
with early stage tumors who were in need of chemotherapy displayed a better relative survival 
than those without chemotherapy for up to about 200 days from chemotherapy, but this effect 
waned thereafter. Among those with early stage tumors that were treated with chemotherapy 
there is a minor proportion of patients who did not receive curative surgery due to the location 
of the tumor. This group with “definitive chemotherapy” (only chemotherapy, no surgery) 
could also have influenced the diminished long-term survival in the group with chemotherapy 
treatment.  
Study IV therefore contributes with the knowledge that curative management of patients with 
early gastroesophageal cancers seems to influence the survival of these patients significantly. 
Time to surgery seems to be a key prognostic factor.  
More finely stratified analyses according to histology, location and specific tumor stage could 
not be performed, but this would be feasible with the material from NREV. If the results from 
study IV are confirmed, it could be worthwhile to stress the importance of shortening time to 
surgery among early stage gastroesophageal cancer patients with curative treatment intention. 
Further, the survival among patients who were intended to have curative treatment at diagnosis 
but who were found to have late stage tumors was analyzed. Among these patients, the 
difference between those with versus those without chemotherapy was not statistically 
significant. In this group there should be a minority of patients who had worsening of their 
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health status or tumor progression from the date of diagnosis until the planned start of 
treatment, which made them unsuitable for curative treatment. Compared to late stage palliative 
patients, the late stage curative patients had a much better survival. The late stage curative 
patients without chemotherapy even had a better survival than late stage palliative patients with 
chemotherapy. This difference should largely be attributed to the effect of surgery. It is likely 
that sub-groups of late stage curative patients had statistically significant better survival among 
chemotherapy patients than those without chemotherapy, but we did not have a sample size 
large enough for investigating this further.  
Moreover, there were relatively few patients in the palliative group with early stage tumors and 
they did not have a statistically different survival probability in the chemotherapy vs. no 
chemotherapy group. Their survival was comparable to late stage palliative patients with 
chemotherapy treatment. This group most likely had factors making them unfit for curative 
surgery and this strongly affects their survival probability. The reasons for not offering this 
group curative surgery could not be assessed, but credible reasons could be patient-related 
factors such as co-morbidities, low performance status or otherwise frail health. 
Many of the patients in study IV were late stage palliative patients (43%) and in this group the 
survival was significantly better for patients with chemotherapy than without. Late-stage 
palliative patients without chemotherapy had the worst survival in our study cohort. In this 
large group of patients there are most certainly individuals with aggressive tumors. With 
continued research on the etiology of these tumors it might be possible to find biomarkers to 
detect these patients earlier and provide primary prevention and/or develop targeted therapy 
based on their molecular/genetic setup. 
In summary, chemotherapy seems to have a significant influence on the survival of early stage 
patients in the curative intention group and late stage patients in the palliative intention group 
compared to no chemotherapy.   
6.2.1.2  The choice of first line chemotherapy 
In study IV there was some variation in the choice of first line chemotherapy treatment among 
patients with the same treatment intention at diagnosis. The study period from 2008 to 2013 
was before the pivotal clinical trials that have shaped current treatment recommendations. In a 
similar study on the period after 2013 one would expect to see less variation in the choice of 
treatment. The basis for the variation is unknown, but it seems it was not random. To begin 
with, there was a “preferred” choice of chemotherapy in all three sites: esophageal (cisplatin-
fluorouracil), gastroesophageal junction (cisplatin-fluorouracil) and gastric cancer (epirubicin-
oxaliplatin-capecitabine), which more than half of the patients were given in the curative 
treatment group. This pattern was most pronounced in the curative gastric cancer group. A 
similar pattern but not as distinct and with different chemotherapy regimens was noted in the 
palliative treatment group. A preference for cisplatin-fluorouracil in the curative group was 
noticed, but the combination oxaliplatin-fluorouracil was more common in the palliative group. 
This could be due to the “milder” toxicity profile of oxaliplatin compared to cisplatin (124). 
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6.2.1.3 Large variation in dose and duration 
In study IV, the chemotherapy dose and duration and subsequent lines of chemotherapy were 
assessed but not reported due to the small sample size that did not allow for stratification on 
those variables. As expected, the inter-individual variation was high.  
The dose and duration of the treatment is generally based on subgroup characteristics such as 
age, sex, body surface area or BMI, renal function, co-morbidities, co-medications etc. The 
goal with adjusting the dose and duration of the treatment based on subgroup characteristics is 
to reach the exposure necessary for treatment effect without unacceptable toxicity. Based on 
these parameters the inter-individual variation in dose and duration is generally quite high.  
Currently, the individual exposure to gastroesophageal chemotherapy drugs is measured 
mainly by following the effect on the tumor and organ-specific toxicities by monitoring the 
patient with blood samples and asking the patient at follow-up visits. Adjustments to the dose 
and duration are made along the way if the effect is undesirable or the patient cannot tolerate 
the treatment.   
6.3 STRENGTHS AND LIMITATIONS 
The main strength of this thesis is the broad scope which includes both esophageal and gastric 
cancer. The rationale for studying both cancers in the same thesis was the knowledge from 
previous studies or guidelines that esophageal and gastric cancer patients share some common 
epidemiological risk factors and treatment strategies, but in this thesis we explored common 
biological pathways to cancer development, and the survival effects following chemotherapy 
treatment. These comparisons have been complex because gastroesophageal cancers are not 
just esophageal or gastric cancer but many different cancers within those two organs. 
Nevertheless fruitful conclusions can be drawn from comparing biological markers for these 
diseases. An altered gastric mucosal microenvironment is associated with an increased risk for 
esophageal squamous cell carcinoma in the middle and lower third of the esophagus, but 
esophageal mucosal lesions do not appear to be associated with an increased risk for gastric 
non-cardia adenocarcinoma and only a moderate increase in the risk for gastric cardia cancer. 
Secondly, a strength of exploring biological markers is that we helped to set the scene for more 
goal-oriented future studies on biomarkers for pre-malignant lesions of gastroesophageal 
cancers.  
Further, this thesis encompasses studies in both high- and low-risk areas of gastroesophageal 
cancers which is necessary when looking for etiological biomarkers and not just associations 
or population-specific risk factors. 
Last but not least, in this thesis study designs with high precision and validity were employed. 
The large sample size in study I-III enabled the exploration of associations with better statistical 
power than previously. The high completeness of the registers used in study I, II, IV and the 
good response rate in study III is another strength. In addition, extensive efforts were made to 
control for possible sources of bias and confounding in all studies I-IV. 
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In spite of all efforts to deliver precise and valid estimates, there are clear limitations with this 
thesis. In the register-based studies the main limitation was the lack of validation of 
histopathology codes. Re-assessments of the histopathology samples to validate the accuracy 
of the diagnosis would have been preferable but was not feasible within the scope of this thesis. 
Future validation studies of the histopathology diagnoses for gastric and esophageal lesions are 
therefore warranted.  
 
The main limitation with our case-control study (study III) was the lack of a validation study 
of the serological gastric atrophy cases with endoscopy.  
 
7 CONCLUSIONS 
First, we conclude that family history of gastric mucosal lesions can be used for further risk 
stratification of gastric non-cardia adenocarcinoma among healthy individuals or individuals 
with various gastric lesions. 
Second, we conclude that the risk for esophageal adenocarcinoma associated with 
gastric/glandular metaplasia is similar to the risk among patients with intestinal metaplasia.  
Third, we confirm the association between gastric atrophy and esophageal squamous cell 
carcinoma, and its interaction with poor oral health to further increase the risk, in a high-risk 
region in China. 
Last, we conclude that the choice of chemotherapy regimen for esophageal and 
gastroesophageal junction cancer patients may predict the survival among patients in the 
curative intention treatment group. 
 
8 FUTURE STUDIES 
8.1 FAMILY-CLUSTERING  
Future studies of molecular changes underlying the Correa cascade should include patients with 
a family-history of the gastric mucosal lesions, including gastric atrophy, intestinal metaplasia 
and dysplasia. Particularly patients with siblings who also have gastric mucosal lesions could 
enable meaningful insights into the pathogenesis. Furthermore, studies exploring biomarkers 
for family-clustered gastric non-cardia cancer may also include healthy individuals or 
individuals afflicted with various gastric lesions with family history of gastric mucosal lesions. 
Future genome-wide association studies should map host and H. pylori related genetic 
polymorphisms in family-clustered non-cardia gastric cancer. It might help understanding the 
necessary causal factors among high-risk individuals. In the long run, this might enable the 
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identification of a more specific group of high-risk individuals in need of surveillance and/or 
primary prevention.  
There is also the question of when to start the surveillance of first-degree relatives and how 
often. Future epidemiological studies could help to improve risk stratification by considering 
geographical region, age-group and number of relatives affected. But modelling cost-
effectiveness studies and ultimately clinical trials could help answer this question definitely. 
8.2 PRECURSOR LESIONS 
The findings in study II regarding the association between columnar metaplasia and esophageal 
adenocarcinoma should be tested in other populations, preferably based on histopathological 
data. A validation of the Barrett’s esophagus diagnosis in the Swedish histopathology registers 
is also warranted.  
A very exciting approach to continue exploring the findings in study II regarding the biological 
mechanisms of esophageal adenocarcinoma development based on histopathology would be to 
study molecular/genetic/epigenetic differences between non-dysplastic Barrett’s esophagus 
samples in patients who progressed to low-grade dysplasia vs. those who did not progress. 
Another approach could be to perform a nested case-control among patients with esophageal 
biopsies stored in Swedish pathology departments several years prior to their cancer diagnosis. 
Future studies could determine molecular/genetic differences between EAC patients with a 
prior diagnosis of Barrett’s esophagus, compared to patients without a prior diagnosis of 
Barrett’s esophagus.   
The continued research regarding the association between gastric atrophy, poor oral health and 
esophageal squamous cell carcinoma should focus on testing the biological mechanism 
underlying this association. Preferably by studying the role of altered oral or gastric microbiota 
in the developments of esophageal squamous cell carcinoma among patients with gastric 
atrophy verified by endoscopy and histopathology. 
8.3 PERSONALIZED TREATMENT 
There is substantial work to do within the area of personalized medicine in gastroesophageal 
cancer patients.  
To begin with, a validation study of the findings in study IV using the nation-wide NREV 
register linked to nationwide data from the SALT register would be feasible and justified. 
Different treatment strategies and chemotherapy choices across the country might not make it 
possible to validate our findings from the Stockholm-Gotland region, but important 
conclusions could be drawn regarding the survival outcomes from past chemotherapy 
treatment. In such a study, a better control for delivered surgery and oncology treatments could 
hopefully be reached. 
The INCA register is managed at the Regional Cancer Centers in Sweden and contains data 
about health care delivered to cancer patients, including the delivery of new chemotherapies 
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reported from the care-givers since 2018. The INCA register provides an excellent platform for 
future comparisons of the survival outcomes of gastroesophageal cancer patients who received 
various chemotherapy regimens. 
There is a major gap between the current knowledge of dose optimization in chemotherapy and 
the clinical practice. Future clinical trials evaluating the survival benefit of therapeutic drug 
monitoring for certain chemotherapy drugs given to gastroesophageal cancer patients are much 
needed. In addition, it would be a major achievement to find clinically useful biomarkers that 
can predict responders and non-responders to chemotherapy prior to treatment. Prospective 
clinical validation studies of suggested biomarkers from research studies could potentially be 
very valuable.  
 
9 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Cancer i magsäcken och matstrupen hör till de dödligaste cancerformerna i världen. Det är bara 
en av tre patienter med magsäckscancer och en av sex patienter med matstrupscancer som lever 
fem år efter sin diagnos. Överlevnaden är avsevärt bättre bland patienter där man kan operera 
bort tumören, men majoriteten av patienterna, så många som 70-80% har så pass spridd cancer 
att detta inte är möjligt. Därför får de flesta patienter med spridd tumör endast lindrande eller 
ingen behandling. Både patienter som har en utsikt att bli botade och patienter som planeras 
för lindrande behandling kan få cellgifter. Tyvärr följer man sällan upp överlevnaden bland 
patienter som fått olika cellgifter.  
Det är högst önskvärt att minska det lidande som cancer i magsäcken och matstrupen orsakar. 
En hörnsten i att minska sjukdomsbördan är att förstå vad som orsakar dessa sjukdomar. Även 
om forskningen har ökat förståelsen för nödvändiga omständigheter för cancerutveckling så 
vet vi fortfarande inte orsaken till cancer i magsäcken och matstrupen. 
Målet med den här avhandlingen har varit att utforska förstadier till cancer i magsäcken och 
matstrupen samt studera hur valet av cellgiftsbehandling påverkar överlevnaden hos patienter 
med cancer i magsäcken och matstrupen. De fyra studier som ingår i avhandlingen baserades 
på hälsoregister i Sverige (studie I, II och IV) samt en fältstudie i ett högriskområde i Kina 
(studie III). I studie I undersöktes hur stor risk familjemedlemmar löper att få magsäckscancer 
om de har en släkting med förstadier till cancer i magsäcken. I studie II beräknades risken att 
utveckla cancer i magsäcken och matstrupen hos patienter som hade tagit vävnadsprover från 
matstrupen. I studie III prövades sambandet mellan slemhinneförtvining i magsäcken och 
risken för skivepitelcancer i matstrupen. I sista studien jämfördes överlevnaden hos patienter 
med cancer i magsäcken och matstrupen beroende på vilken cellgiftsbehandling de fått.  
Risken för cancer i magsäcken var 50-60 % förhöjd bland individer med familjemedlemmar 
(föräldrar, syskon eller barn) som hade förstadier till cancer i magsäcken än den allmänna 
befolkningen i Sverige. Nästa upptäckt var att patienter som har cylindercellsförändringar i 
matstrupen, löpte en tio gånger ökad risk att utveckla körtelcellcancer i matstrupen jämfört med 
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den allmänna befolkningen i Sverige, vilket var i nivå med ett sedan tidigare känt förstadium 
till körtelcellcancer som kallas Barrett-slemhinna. I den tredje studien var risken för 
skivepitelcancer i matstrupen 60 % högre bland de patienter som hade slemhinneförtvining i 
magsäcken i ett högriskområde i Kina. I den sista studien som genomfördes i Stockholm-
Gotland, upptäcktes att patienter som fick botande cellgiftsbehandling med 
cellgiftskombinationen cisplatin-fluorouracil hade bättre överlevnad om de hade cancer i 
matstrupen (jämfört med karboplatin-fluorouracil), men sämre överlevnad om de hade cancer 
i övergången mellan matstrupen och magsäcken (jämfört med fluorouracil-oxaliplatin).  
Slutsatsen är därför först och främst att man kan använda uppgifter om förstadier till cancer i 
magsäcken för att identifiera personer med hög risk att utveckla magsäckscancer i sjukvården. 
Vidare kan det vara värdefullt att följa upp patienter med cylindercellsförändringar i 
matstrupen, oavsett diagnosen Barrett-slemhinna eller inte. Vidare, bekräftades det omstridda 
sambandet mellan slemhinneförtvining i magsäcken och risken för skivepitelcancer i 
matstrupen som ytterligare förstärks av undermålig munhälsa. Sist men inte minst verkar valet 
av cisplatin-fluorouracil vara förknippat med bättre överlevnad hos patienter med cancer i 
matstrupen, men sämre överlevnad bland patienter med cancer i övergången mellan matstrupen 
och magsäcken. Samtliga fynd bör studeras ytterligare innan de omsätts till användning i hälso- 
och sjukvården.
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